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1. PREFACE
Concern over the abuse of psychoactive substances, particularly amphetamines and barbiturates, emerged
earlv in the 50's. In an attempt to ~ring about unified action for the control of these psychoactive substances a
special international control instrument - the 1971 Convention on Psychotropic Substances - was introduced.
The major aims of the Psychotropic Convention are to control the production, marketing (sale on prescription
only), exportation and importation of psychotropic substances which have dependence producing liability.
The criteria for the inclusion of a psychoactive substance in the 1971 Convention is contained in Article 2,
Section 4 and 5, of the said Convention which also clearly identifies the responsible organs to undertake the
evaluative functions. The article mentioned above require that:-
"If the World Health Organisation finds:
a. That the substance has the capacity to produce
i. (l) A state of dependence, and
(2) Central nervous system stimulation or depression, resulting in hallucination or disturbances
in motor function or thinking or behaviour or perception or mood, or
ii. Similar abuse and similar ill effects as a substance in Schedule I, II, III or IV and
b. That there is sufficient evidence that the substance is being or is likely to be abused so as to constitute a
public health and social problem warranting the placing of the substance under international control,
the World Health Organisation shall communicate to the Commission an assessment of the substance,
including the extent or likehood of abuse, the degree of seriousness of the public health and social pro-
blem and the degree of usefulness of the substance in medical therapy, together with recommendations
on control measures, if any, that would be appropriate in the light of its assessment.
The Commission, taking into account the communication from the World Health Organisation, whose
assessments shall be determinative as to medical and scientific matters and bearing in mind the economic social,
legal, administrative and other factors it may consider relevant, may add the substance to Schedule, I, II, III or
IV. The Commission may seek further information from the World Health Organisation or from other ap-
propriate sources".
During the meeting of the Seventh Special Session of the United Nations Commission on Narcotic Drugs
held in Vienna from 2-8 February 1982, the Commission adopted a Resolution 2(S-VII) on Procedure to be
followed by the Commission on Narcotic Drugs in matters of scheduling of narcotic drugs and psychotropic
substances. The Resolution apart from identifying the types of information that should be considered by the
World Health Organisation also requested Member State for "information on the economic, social, legal and
administrative factors related to the abuse of substances being considered for possible scheduling, and to supply
as. complete data as possible on any illicit trafficking in the substances in question" .
Subsequent to the meeting of the Commission, interested Member States, scientists and the Secretariat of
the Commission held extensive discussions to address the request of the Commission. It was noted that the Na-
tional Drug Research Centre, University of Science of Malaysia, a designated United Nations/World Health
OrganisaLion Research and Training Centre in Drug Control, was already undertaking an UNFDAC supported
study on similar lines. Hence it was considered that the centre should expand the existing study and undertake
appropriate analysis in collaboration with UNDND and prepare a report on its findings.
Based on the discussions, a questionnaire was developed by a panel of researchers and circulated to
selected scientists for comments, and based on the suggestions a final questionnaire was prepared. It was
originally envisaged that the questionnaire would be circulated to all Member States by the UNDND; however,
due to technical and administrative difficulties, it was decided to reduce the "additional" data gathering activity
to a sample of fifteen anglophone countries. This study shall be called throughout this report the IMPACT -
study because one ofits objectives was to gather data on the IMPACT of scheduling substances under the 1971
Convention.
Data gathered by t,he United Nations, through the normal procedure of Annual Reports etc. was also
available to the researchers who undertook extensive analysis. Concurrently with this data gathering/analysis ac-
tivity, a literature survey of published report etc. was undertaken.
Initially, the objective of this report was to linrit the review only to the economic, social, legal and ad-
ministrative factors related to the abuse and illicit traffic as well as to assess the impact of scheduling substances
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under the 1971 Convention. However, early in the project, it became very apparent to the research team that
data on the diverse elements of required information exist in different isolated packets. In order to provide a
comprehensive picture it was decided that this Report should present an analysis of the current understanding
(knowledge) on all elements of information requested in the 1971 Convention. Hence it is essential that this
Report is considered as being complementary and supplementary to WHO and other reports.
Further, since the Commission decided to consider the benzodiazepine group of substances for possible
scheduling in 1983, this group of substances have been chosen for our review. The methodology developed in
this project, obviously could be and should be applied for all future substances considered for scheduling.
The report presented here las assembled and analyzed data from various sources including information
from the IMPACT - study, and reviewed the literature in order to address the following issues with regard to
the benzodiazepines:
i. The pharmacology, toxicity and therapeutic use;
ii. Overuse, abuse potential and the extent of abuse and their consequence, social and public pro-
blems, as well as illid drug traffic. Existing data, as well as new data are critically examined in
relation to the general problem of drug abuse to ascertain the real extent to which it causes social
and public health problem;
Ill. The extent to which national legislation can effectively address the problems of benzodiazepine
abuse and the effectiveness and usefulness of international control in addressing these same pro-
blems;
IV. The economic, social, legal and administrative aspects as well as the impact of controlling the ben-
zodiazepines internation~,lly was assessed.
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2. BENZODIAZEPINES - WHAT ARE THEY?
HISTORY
The first members of the family of the 4,5-benzo(hept)-1 ,2,6-oxidiazines were synthesised by Sternbach in
Poland in 1933. In 1955, this group of compounds were taken up at the Hoffmann La Roche Laboratories in
Nutley, N.J., by Sternbach. These research efforts led to the discovery and development of Chlordiazepoxide
(Librium) as the first of a group of clinically useful and pharmacologically unique anxio1yti~(lgents (Sternbach,
1973). Since then thousands of benzodiazepine compounds have been synthesized and tested pharmacologically
and many have been used clinically.
CHEMISTRY
The 1,4-benzodiazepines all have the following basic structure: R1 is usually an electron-withdrawing
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FIGURE 1
substitutent, R2 is usually an alkyl group (or hydrogen). All important CNS-depressant benzodiazepines contain.
a 5-aryl or a 5-cyclohexyl group. Other than that . .the structure-activity relationship is not stringent. Electron-
withdrawing substituents at position 7 enhance and electron-releasing as well as large substituent groups sup-
press pharmacological activity. Substitution with a 7-nitro group enhances anticonvulsant activity. Substitution
at position R3 with electron-withdrawing groups enhances potency (Harvey, 1980).
With the exception of chlordiazepoxide hydrochloride and flurazepam hydrochloride which are salts and
thus exhibit good solubility in water, most of the other benzodiazepines are usually present as free bases and are
thus poorly soluble in water but easily soluble in methanol and chloroform. Solutions of benzodiazepines in
methanol and absolute ethanol are very stable. However aqueous solutions decompose under acid and alkali
conditions (Clifford, 1974).
BASIC PHARMACOLOGY AND MECHANISM OF ACTION
It is usually assumed that the benzodiazepines as a class of drugs all ex~rt the same qualitative actions and
possess the same mechanisms of action, even though there are quantitative differences in their pharmaco-
dynamic activity. Clinically, however, diazepam, chlordiazepoxide, oxazepam are used as anxiolytics as well as
sedative/hynotics whereas other cogeners like flurazepam and nitrazepam are used principally as sedative/hyp-
notics.
The most characteristic and specific action of the benzodiazepines is the disinhibition or the normalization
of behavioural responses suppressed previously by punishment or by absence of reward. This is clearly exhibited
in experimental conflict situations where behavioural responses inhibited by punishment reappear after the ad-
ministration of benzodiazepines. Such conflict experiments are used in the screening of anxiolytics. .
The benzodiazepines also increase behaviour responses in non-reward situations. Whereas the release of
behavioural responses suppressed by punishment is considered due toa reduction of fear, the increase in non-
rewarded behaviour indicates an anti-frustration activity. The benzodiazepines also increase exploratory activity
and this is thought to be due to the reduction in the fear of novelty. '
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This specific activity is ~sually not exhibited by other groups of psychotropic drugs, with minor exceptions
e.g. alcohol, barbiturates, meprobamate, valproate etc. However, the latter drugs exhibit a very narrow range of
dissociation between anticonflict and unspecific "sedative" effects.
Anti-aggressive activity of the benzodiC'zepines has been demonstrated in spontaneously aggressive
monkeys and wild animals, in mice made aggressive by isolation or by foot shock, and in affective defensive
behaviour induced by brain stimulation in cats, monkeys and rats. However, the benzodiazepines did not affect
muricidal activity and brain lesion induced aggressiveness, in fact, they even enhanced aggressive activity in
grouped male mice (Knoll et. aI., 1980).
Benzodiazepines produce various effects which are categorised clinically as "sedative" effects but in ex-
perimental pharmacology are termed "reduced arollsal". This effect is manifested clinically as an increase in
amount of sleep, reduction of sleep latency, decrease in wakefulness and restlessness during sleeping, thereby in-
creasing sleep comfort.
The benzodiazepines are quite potent in blocking convulsions and epileptiform EEG activity induced by
chemical agents like pentylenetetrazol, pictrotoxin, bicuculline and 3 mercaptopropionic acid. Strychnine and
electroshock induced seizures are suppressed at somewhat higher doses. The mode of action by which this effect
is attained is via the prevention of the subcortical spread of the seizure activity. The benzodiazepines do not
abolish or arrest the discharge of the seizure focus. They also block seizures occuring during ethanol or bar-
biturate withdrawal and also photic sefzures in baboons. Recently, it has been reported that the benzodiazepines
are effective for controlling seizures induced by pyrogens. Flunitrazepam, tirazolam, clonazepam, nitrazepam
and bromazepam are pronounced in their anticonvulsant effects as compared to the other benzodiazepine
derivatives. Inman diazepam is especially useful j!'. controlling status epilepticus.
The benzodiazepines produce muscle-relaxant effects in experimental animals as well as in intact <mimals
i.e. with normal muscle tone. The muscle--relaxant effect appears at doses which are far below those needed for
an overt CNS depression. However, Jhis seems in general not to be the case in man. Although the ben-
zodiazepines in therapeutic doses do not exhibit a direct action on peripheral autonomic functions, they reduce
the autonomic responses to direct electrical stimulation of the hypothalamus and other brain structures, and
autonomic r~exes induced by peripheral stimuli. This is the rationale for the use of the benzodiazepines in
various psychosomatic, cardiovascular, gastrointestinal, urogenital and endocrinological disorders. Ben-
zodiazepines enhance primary afferent depolarization subserving presynaptic inhibition and reduce gamma-
motoneurone activity and mono - and polysynaptic reflexes in the spinal cord. They depress the spontaneous
and evoked neuronal activity in various brain areas. In high intravenous doses, the benzodiazepines produce
anterograde amnesia (Haefely, 1980; Haefely, et. aI., 1981; Knoll, 1980; Harvey, 1980).
The mechanism of action of the benzodiazepines is postulated to be in some way related to the action of
GABA (Haefely et. aI., 1981). In 1977, Squires and Braestrup and Mohler and Okada initiated binding studies
which led the way for research on benzodiazepine receptors. They discovered that 3H-diazepam was specifically
bound to a protein in crude rat brain membranes. These benzodiazepine receptors were not found outside the
Central Nervous System. The presently accepted hypothesis on the relationship between GABA and ben-
zodiazepine receptors is that the GABA receptor-chloride ionophore complexes contain in addition receptor sites
for benzodiazepines (and also for picrotoxin and barbiturates). Evidence indicates that all benzodiazepine recep-
tor sites are associated with GABA receptor-chloride ionophore complexes but the latter may exist in a form in-
dependent of the benzodiazepine receptor. The suggestion that these GABA receptor-chloride ionophore com-
plexes also contain picrotoxin/barbiturate recognition sites is borne out by picrotoxin binding studies and by the
fact that barbiturates enhance both GABA and benzodiazepine binding to their receptor sites. Present emphasis
of research is focussed on the search for a freely diffusable extracellular endogenous ligand. At present, inosine,
hypoxanthine, nicotinamide, thromboxane H 2 and betacarboline esters have been implicated as putative en-
dogenous ligands (Knoll, 1981).
The benzodiazepine receptors are unevenly distributed in the brain regions. The cerebral and cerebellar
cortical areas as well as the limbic areas have higher densities of benzodiazepine receptors, while other areas have
lower levels (Squires and Braestrup, 1977; Mohler and Okada, 1977; Speth et. aI., 1978). The regional variations
in receptor density is .species dependent in some instances.
Current evidence points to the fact that the sensiyity of the receptors may be increased by various chemical
agents, especially GABA and its agonists. Also the~number of binding sites may be altered after seizures by
pretreatment by chemical agents like diphenylhydantoin (Tallman, J.F. 1980). An interesting observation made
during these binding studies is that complete occupancy of these binding sites is not necessary to protect against
seizure activity.
PHARMACOKINETICS
As a -class the benzodiazepines are rapidly and almost completely absorbed from the gastro-intestinal tract,
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reaching peak blood concentration shortly after administration (Kaplan, 1980). For example, diazepam, one of
the most rapidly absorbed compounds, reaches peak blood concentrations within one hour. The extent of pro- .
tein binding in the plasma varies with the compound concerned. Generally, it falls within the range of 85-95070.
An exception is flurazepam, which is minimally protein bound., The plasma concentration kinetic patterns of the
benzodiazepines are consistent with the two/three compartment open pharmacokinetic model, the three com-
partment model being more appropriate for more lipid soluble derivatives. Enterohepatic circulation may cause
a secondary surge in plasma concentration hours after drug administration (Harvey, 1980). Most biotransforma-
tion occurs in the liver and excretion is mainly in the form of conjugated glucuronides. Many pharmacologically
active metabolites may be formed as a result of biotransformation on the 1,4-diazepine ring. For example,
diazepam has three principal active metabolites, namely N-desmethyldiazepam, oxazepam and temazepam.
BENZODIAZEPINE ANTAGONISTS
While working on a series of imidazodiazepines, potent inhibitors of benzodiazepines were discovered
recently in the Roche laboratories. From a large group of these compounds, the compound Ro 15-1788 has been
selected and tested clinically. This antagonist inhibits the specific binding of 3H-diazepam to the receptors and
antagonises, antipunishment, anticonvulsant, muscle-relaxant and the polysynaptic depressant effects of ben-
zodiazepines. The antagonistic activity is specific for benzodiazepine effects mediated by the central ben-
zodiazepine receptor. The structure of the antagonist, Ro 15-1788 is as shown in Figure 2 (Hunkeler et. al.,
1981).
FIGURE 2: Structure of Benzodiazepine Antagonist, Ro 15-1788
TOXICITY
Th~ commonl~ obs:rved ~ide effects include drowsiness, confusion, ataxia, excitement, vertigo, transient
hypotenslOn, gastromtestmal dIstress and skin rashes (Bellantuono et. al., 1980).
. The major side effect is sedation. However, tolerance or adaptation occurs and the initial drowsiness if ex-
pen~nced, usually abates over time with repeated administration. Serious intoxication and death due to the in-
¥estlOn of benzodiazepines alone are extremely rare. Serious sequelae of sucidal attempt or death usually occur
m a.ssoci~tion with concomitant intake of alcohol!other drugs. Most authors are of the opinion that the ben-
zodlazepmes are very safe drugs and death as a consequence to benzodiazepines alone is almost impossible.
THERAPEUTIC USE
.By the ~n~r?duction of th~ first benzodiazepine (chlordiazepoxide) in 1960 a major change in therapeutic
practice was mitiated, Four mam actions characterise this class of drugs:
anxiolytic
muscle-relaxant
antiepileptic
sedative-hypnotic
d'ff These four action components are present in all benzodiazepines so far on the market· however they may
I ~r fr~m each other in the relative strength o~ the four components. Research is still od going to find ben-
z~d;az,epmes that have a ~ore selective action e.g. anxiolytic without the sedative-hypnotic component. Since
t e dIscovery of antagomsts and - more important from this point - of partial antagonists this hope does not
seem totally unrealistic.
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The main indication at introduction was anxiolysis, and this has remained a major indication for these
drugs, as anxiety is widespread in most of modern societies. Anxiety neurosis is a wide field, and many patients
who have difficulties of coping '>,'ith their life problems because they are anxious benefit from this sort of
medication. This was demonstrated by a great number of studies again and again, many ofwhich were well con-
trolled and fulfilled the criteria of the most stringent regulatory authorities. In this field thebenzodiazepines are
considered a major innovation, not only because they were better anxiolytics than the then widely used bar-
biturates but also because they are much less toxic and by that fact curbed the number of barbiturate intoxica-
tions often lethal. It was soon discovered that anxiety present in somatic and psychosomatic conditions respond-
ed well to these anxiolytics; this widened the field of indication to a great extent. Finally the anxiolytic action of
benzodiazepines made them a usef,J! adjunct in the treatment of depression when anxiety was a prominent
feature of it. Though strictly controlied clinical trials over long periods (a year or longer) are not available, there
is good clinical evidence that anxiety can be relieved for long periods (years) by the benzodiazepines. This
evidence is based on the reappearance of anxiety after withdrawal of treatment for long periods (Rickels, 1982).·
It has to be stressed that benzodiazepines should be reserved for the treatment of pathological anxiety; they are
not indicated to cope better with everyday stress. The question to what extent overprescription and overuse in
this respect have been practiced will be treated in a later chapter.
.The muscle relaxing action of benzodiazepines was only discovered in the second preparation on the
market, diazepam, as it showed this property in a more pronounced way than chlordiazepoxide. It has found a
wide field of indication, quantitatively the most important being muscle spasms accompanying rheumatic
disease in the wider sense of the word. Clinically of little importance is the relief from muscle tension in
decerebrate rigidity, impressive as the demonstration of this may be in experimental animals. However in tetanus
which leads to reflex muscle spasm, the muscle relaxing activity of benzodiazepines can be life saving. Before the
advent of the benzodiazepines a few cases of severe tetanus could be saved by curarization and artificial respira-
tion of the patient for weeks, a procedure that needs all the facilities of a modern, well equipped intensive care
unit with a large staff of highly skilled personnel. This method is available in industrialized countries only in
highly sophisticated hospitals and rarely at the disposal of patients in developing countries. All the more impor-
tant for them is treatment by benzodiazepines, especially because tetanus of the new born is not infrequent in
developing countries .
.... The antiepileptic activity of !he ben70diazepines was known from the experimental screening since the
development of chlordiazepoxide, the first benzodiazepines introduced into therapy. This activity is still used as
a screening procedure for new products. However the great hopes set into the benzodiazepines for the treatment
of the average epileptic patient have not been fulfilled. Some preparations with experimentally pronounced an-
tiepileptic medication already known and used, but none of the benzodiazepines was able to replace the former
antiepileptics (phenobarbitone, hydantoins etc.) to any relevant extent. Furthermore there is some evidence that
the antiepileptic efficiency of benzodiazepines diminishes in the course of weeks or months in many cases, in
contrast to what has been experienced with the anxiolytic action of these drugs. This is all the more disappointing
as epileptics are for the most part in need of life long treatment. However there is one epileptic ~ondition in
which benzodiazepines have brought on a major advantage. This is status epilepticus, life-threatening, a condi-
tion seen e.g. in acute cerebral trauma, in severe meningitis (with encephalitis), in malaria, and in chloroquine
and cocaine intoxication. 20 years ago treatment of status epilepticus was a cauch~mar for the clinician because
no reliably efficient medication was available. Since about 15 years intravenous diazepam has become the treat-
ment of choice since by this measure status epilepticus can be stopped in almost every case. It is then a life saving
drug. Malaria and chloroquine intoxication (mostly voluntary with the objective of abortion) are frequent in
developing countries. There this life saving antiepileptic activity is of special importance. In an African study
mortality of chloroquine intoxications has been reduced from 35OJo to 5OJo by the introduction of intravenous
diazepam in status epilepticus.
The sedative hyPnotic action of the benzodiazepines has led to the introduction of a series of substances of
that class as hypnotic drugs. They have soon replaced former hypnotic drugs like barbiturates to a large extent in
the prescription practice and thereby also in the market. One major advantage over the barbiturates is the high
safety margin of the benzodiazepines. Voluntary or accidental intoxication by benzodiazepines is almost never
lethal, in contrast to the barbiturates. There is also a definitely smaller dependence producing potential of ben-
zodiazepines as compared to the barbiturates in experimental studies (Yanagita, 1973). However, the decisive
factor in the acceptance of benzodiazepine hypnotics may have been, that the sleep induced by them is of better
quality, nearer to natural sleep, than the sleep brought on by barbiturates, as can be judeed from clinical as well
as from electro-physiological data (e.g. lesser disturbance of REM sleep).
The sedative and sleep-inducing properties of benzodiazepines have been taken advantage of by
anaesthesiol0gists. Several of these hypnotics (including diazepam) have found large application as premedica-
tion and as induction agents for narcosis. As they produce amnesia without putting the patient in deep narcosis
they are used extensively in diagnosticprocedures , in minor surgery and in dentistry, in hospital as well as in am-
bulatory practice. The advantages of benzodiazepines in the anaesthetic problems of developing countries have
be~ stressed by several authors (Aderoju, Nigeria, 1978, Yanov and Kujan, Ethiopia, 1981).
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It may be fit at this point to mention two clinical studies that relate to social issues of the therapeutic use of
benzodiazepines. The usual objective of clinical investigations is to determine efficacy and side effects. These
studies go further and investigate social effects of diazepam, the aim of a psychotherapeutic a'ction being not on-
ly relief of the patient but also his integration in his surroundings. The WHO Expert Committee on drug
dependence has stated that true drug abuse characteristically gives rise to adverse social effects not only on the
individual abusing the drug but also on the abuser's immediate social surrounding, family, friends, work situa-
tion and society as a whole. Proctor, (1981) compared the effects on work place parameters of psychoactive ver-
sus non-psychoactive medication with special emphasis to diazepam. He found that diazepam is not associated
with any difference in performance or in accident or absentee rate above that observed in patients taking any
other type of medication. The results from this study showed no negative effects in the work place associated
with diazepam use. Whybrow, Matlins and Greenberg investigated the social impact of psychoactive drugs in a
survey of the perceptions of prescribing and non-prescribing health practitioners. Three categories of drugs had
a beneficial effect on anti-social behaviour.
major tranquillizers
anti-depressants
minor tranquillizers
Practitioners singled out minor tranquillizers for being most effective in ameliorating behaviour disruptive
of family life, verbal and physical abuse of family members, and neglect of family. Practitioners identified
mi;lor tranquillizers as the drug they most often prescribed or saw prescribed in order to reduce dependence on
alcohol (by easing the symptoms of withdrawal). While the above three drug categories were judged in over 90070
to contribute to improved quality of life, stimulants, barbiturates and alcohol in the majority of cases did not
improve quality of life.
Starting from these data the Institute for Social Research of Michigan University has started an extensive
study on the effects of benzodiazepines in the social context. Preliminary results show a conservative use of ben-
zodiazepines by prescribing physicians and by patients and a beneficial effect on factors decisive in quality of
life.
DEPENDENCE
In studies of drug abuse and dependence, two distinct types of dependence can be distinguished, i.e.
physiological (physical) dependence and psychological dependence. Physiological dependence manifests itself by
the fact that on discontinuation of drug treatment a time limited withdrawal reaction follows; this however is
prevented by continued drug treatment. Psychological dependence is manifested by a tendency of a subject to
repeatedly seek and self-administer a drug (Woods et. al., 1982).
Experimental studies of dependence usually involve laboratory animals (usually rats, monkeys, baboons)
as well as observation on humans through clinical case studies or controlled trials.
PHYSIOLOGICAL DEPENDENCE
Experimental animal studies on physiological dependence are of two major types, i.e. primary dependence
studies and cross dependence studies.
In primary dependence studies, the test drug is repeatedly administered for a period of time and then sud-
denly discontinued. The withdrawal signs, if any, are then observed and recorded. Studies of this nature have
been widely performed using various benzodiazepines.
In cross dependence studies, dependence is developed to some prototype compound of known dependence
capacity and the capacity of the test drug to prevent or reverse withdrawal from the prototype compound is ex-
amined. The assumption is made that a drug that completely reverses the withdrawal symptoms of a prototype
compound will produce a similar type of dependence when repeatedly administered. This assumption holds true
with the narcotic group of drugs but with regards to sedative-hypnotic compounds it has not been fully
validated. For the benzodiazepines, the prototype compound is usually barbital or phenobarbitone. Cross
dependence studies in rodents as well as monkeys indicate that all of the benzodiazepines examined so far sup-
press barbital withdrawal similarly and only differ in their potency (Yanagita, 1981).
In regard to benzodiazepines, comparison of data is made difficult by the fact that varying dose levels have
been used and the dosing regimens used vary with respect to the frequency of administration, the duration of ad-
ministration and whether the dose is kept constant throughout the duration or whether the dose is increased in
some specified manner. In addition, the doses used are usually many times higher than normal therapeutic doses.
In spite of this, most studies are equivocal whether physiological dependence can develop in experimental
animals. A study by Boisse et. al., (1981) has shown that the physiological dependence phenomenon is dependent
on the dose level as well as the duration of administration using chlordiazepoxide in rats. A comparison of the
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dependence producing effect of chlordiazepoxide and phenobarbital using the chronically equivalent dosing
technique Boisse et. al., (19§'i) as well as Martin et. al., (1982) have found that the withdrawal symptoms observ-
ed are qualitatively different. There is no compelling ~vidence to date to demonstrate any difference in the
dependence producing effect of the various benzodiazepine agents (Woods et. aI., 1982). The newly developed
benzodiazepine antagonist Ro 15-1788 has been used successfully to precipitate withdrawal in benzodiazepine
dependent animals (Lucas and Griffiths, 1982b, c,; Rosenberg and Chiu, 1982 and McNicholas and Martin,
1982).
In humans, case reports and controlled studies provide evidence that physiological dependence can
develop, especially at higher daily dose levels and with longer duration of drug treatment (Rickels, 1980). Some
evidence is also available for the development of physiological dependence in patients on benzodiazepine therapy
using therapeutic doses, although the incidence of this is small (Woods, 1982).
PSYCHOLOGICAL DEPENDENCE
Experimental studies on psychological dependence using animals involve the self-administration technique
using oral, intragastric and intravenous routes of administration. In summarizing available studies using oral
benzodiazepine intake Woods (1982) concludes that none of them has shown a substantial preference of drug
solution over vehicle solution. In studies involving the intravenous or intragastric'self-administration of drug
solutions, drug delivery is used as a reinforcer for a certain response performed by the animal, such as pressing a.
lever. Comparison with the rate of self-administration of the control vehicle provides a measure to evaluate the
drug reinforcement activity. The procedures used for these self-administration studies may vary from a simple
one response/one injection ration at any time to a more complicated program like a fixed ratio of ten responses
to one injection schedule, limited to a certain duration of experimental session. The majority of experiments in
which there is unlimited access to the drug solution has been performed on monkeys. Yanagita and Takahashi
(1973), Yanagita et. al., (1975), Yanagita and Kiyohira (1976), Yanagita et. aI., (1981), reported somewhat
various degrees of reinforcing properties for diazepam, chlordiazepoxide, halazepam, fludiazepam, medazepam
and other benzodiazepines. Gotestam (1973) using experimental rats provided some evidence of the reinforcing
properties of medazepam. However, these findings are not universally accepted. Weawer (1975) and Altshuler
and Philips (1978), using a model with intragastric administration, found that diazepam did not maintain self-
administ9ation. Hackett and Hall, (1977) found the same lack of maintained self-administration for intravenous
diazepam. Many of these studies however suffer from various experimental limitations and make their inter-
pretation difficult.
In experimental studies using more complex and intermittent self-administration schedules, diazepam
(Griffiths et. aI., 1981; Yanagita and Oinura, 1982), chlordiazepoxide (Findley et. aI., 1982), clonazepam,
flurazepam (Griffiths, et. aI., 1981) have been shown to be able to maintain self-administration rates above that
of the control vehicle, although only marginally in some cases.
Some of the studies performed compared response rates of benzodiazepines with those maintained by
other drugs. As a class, the benzodiazepines were more efficacious reinforcers than chlopromazine, imipramine,
haloperidol and perphenazine, but were less efficacious reinforcers than pentobarbital, alcohol, secobarbital,
cocaine and codeine (Griffiths et. al., 1980). Thus the results of experimental studies in animals indicate that the
benzodiazepines have reinforcing properties although generally less than other sedative hypnotic agents or
alcohol.
Studies on the reinforcing properties of benzodiazepine in humans may take a variety of approaches.
Generally, studies show that while the benzodiazepines can maintain self-administration their efficacy appears to
depend on the type of population studied, among other procedural factors. Studies by Johnston and Ulenhuth
(1980) using normal population and by De Witt et. al., (1982) using anxious subjects show no preference for
diazepam over placebo. However, Fabre et. al., (1976) and Jick et. al., (1966) reported that insomniacs may
prefer benzodiazepines over placebo which is understandable. Griffiths et. al., (1979, 1980) used pentobarbital
and diazepam on human subjects at doses that produced equivalent subjective effects and reported that sedative-
hypnotic abusers prefer pentobarbitone over diazepam while the high doses of diazepam were preferred over
control vehicle. Higher doses of pentobarbital are associated with more regular self-administration as compared
with high doses of diazepam. In a study by Krypsin - Exner (1975) it is suggested that subjects with a past
history of hypnotic and narcotic abuse are more likely to self-administer higher levels of benzodiazepines than
alcoholics. In another study, Rothstein (1976) expressed the opinion that benzodiazepine use in alcoholics is
quite safe. Studies using subjects suffering from various psychotic and affective disorders (Winstead et. al.,
1974; Balmer et. aI., 1981; Hubbard and Kripki, 1976) suggest that benzodiazepines are self-administered at a
low frequency when available on demand and the frequency tends to decline over time.
The results in general, would indicate that benzodiazepines at normal therapeutic level are not preferential
reinforcers and the rates are lower than for many other sedative-hypnotics. Obviously at higher dose levels -
above therapeutic levels the benzodiazepines do demonstrate a reinforcing property which is higher than the con-
trol vehicle. Current evidence from reinforcement studies do not allow one to distinguish between the different
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benzodiazepines and even the suggestive evidence which is frequently quoted is contradictory.
Several factors have been considered in order to explain apparent differences in clinical observations of
depe.ndence.
Lipid solubility at physiological pH has been invoked on an a-priori-base assuming that higher lipid
solubility might correspond to a higher dependence potential. However the values for lipid solubility as available
are scattered over ~ rather wide range in an unsystematic way so that this value does not seem to be a major fac-
tor in producing dependence liability.
Pharmacokinetic jactors may be more important. Half-life and speed of absorption may be factors in-
fluencing dependence liability. Griffiths et. aI., (1981) and Griffiths and Lucas, (1982) have shown that ben-
zodiazepines with short half-lives like midazolam and triazolam maintain higher rates of self-administration as
compared with drug with longer elimination half-lives like diazepam, clonazepam, clorazepate, flurazepam and
medazepam. Bliding (1974) found that diazepam, a more rapidly absorbed but longer half-life.benzodiazepine,
demonstrated greater subjective effects (including euphoria and dysphoria) than oxazepam, a less rapidly ab-
sorbed and shorter half-life benzodiazepine, but with chronic administration ofdiazepam, these subjective effect
disappeared. On the basis of these results the authors concluded that the more rapidly absorbed benzodiazepines
would tend to have greater dependence potential. Pharmacokinetic studies (Greenblatt and Shader, 1978) have
shown that these subjective drug effects depend more on the rate of increase of blood concentrations than on the
blood concentrations itself; this is in agreement with the report by Bliding (1974).
However these factors cannot be decisive because different countries have problems with different ben-
zodiazepines.
While Thailand reports some abuse problems with diazepam and Singapore with flunitrazepam, Mauritus
has no problem with diazepam but with lorazepam and Australia with oxazepam. A recent study from
Switzerland by Ladewig (1981) shows an abuse prevalence which is in a very narrow range the same for the five
most frequently prescribed benzodiazepines in this country, without correlation to half-life. The Ladewig study
is reported more extensively in the Chapter on Abuse Liability.
One factor which emerges from these findings as most important is market penetration and probably (as a
basis for this) prescribing habits of practicing physicians. At the same time these figures do not allow to differen-
tiate between individual benzodiazepines as to their abuse potential. One could - on a-priori-basis again -
assume, that relatively high dose recommendations might parallel a relatively higher dependence risk. However
there is so far no evidence for such an assumption.
Data on seizures and street abuse indicate that benzodiazepines of long and short half-lives and of various
degrees of lipid solubility are equally abused. Thus the pharmacological, pharmacokinetics and abuse data on
the dependence potential of the benzodiazepines are inconsistent and often contradictory. On the basis of the
current data available, it is not possible to arrive at any distinction as to the relative dependence potential of the
individual benzodiazepines.
One fundamental basis of physiological dependence is the development of physical withdrawal symptoms
on sudden cessation of drug administration. The mechanism of the development of withdrawal symptoms is
practically unknown. Assuming the existence of endogenous benzodiazepine-receptor-ligands Kales et. aI.,
(1978) have proposed a highly speculative hypothesis. The abrupt interruption of benzodiazepine administration
causes a time-lag in production of endogenous benzodiazepine-receptor-ligands suppressed by the exogenously
administered benzodiazepine; this time-lag would be responsible for the appearance of withdrawal symptoms.
Based on this, drugs with plasma half-lives of 6-24 hours would tend to produce severe withdrawal symptoms;
those drugs with plasma half-lives of 36 hours or more are likely to have a mild but longer withdrawal syndrome.
Drugs with a very long half-life may not present any symptoms at all, whereas in drugs with ultrashort half-lives
physical dependence is difficult, if not impossible to develop (Hollister, 1980).
THE 1,5 - BENZODIAZEPINES
In contrast to the other benzodiazepines, Clobazam (Frisium) is structurally different, being a
1,5-benzodiazepine with the nitrogen in 1,5-position of the" diazepine ring rather than at the 1,4 position.
Therapeutic trials indicate that the antianxiety effect of clobazam is comparable to diazepam. Clobazam is
claimed to have minimal muscle-relaxant and hypnotic activity and to cause less 'objectively measurable sedation
or psychomotor impairment than diazepam, chlordiazepoxide or lorazepam. Studies on epileptic patients have
shown clobazam to be initially effective against all forms of epilepsy but it loses it efficacy within a few days or
weeks in more than one-third of the patients.
Like the other benzodiazepines, clobazam is well absorbed orally, reachin~ peak blood levels 1-4 hours
after oral administration. Clobazam undergoes dealkylation to form N-desmethylclobasam as its principal active
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metabolite. In contrast to the 1,4-benzodiazepines, -clobazam does not undergo hydroxylation at the 3-position
of the diazepine ring but rather at the 4-position to form 4-hydroxyclobazam (Brogden, 1980).
Experience so far has shown that clobazam is not exempt from abuse liability similar to the
1,4-benzodiazepines.
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3. BENZODIAZEPINES - SUBSTANCES OF OVERUSE?
Benzodiazepines have had an extraordinary success since their introduction some 20 years ago. Diazepam
was for 10 years or so the most 'Widely prescribed drug in the United States. Benzodiazepines as a class still are
among the most widely used drugs the world over. This fact alone has drawn attention and provoked discussion.
Are they overused?
This question proves to be difficult at a closer look. First exact consumption figures are not easy to get in
many countries. In the United States and in Great Britain the possibility exists to check prescription frequency,
but there is a gap in knowledge between these figures and consumption pattern. Some countries, mainly from the
developing world, have import figures which should (roughly) parallel consumption, But worldwide drug con-
sumption studies are not available for this class of drugs (nor for other classes).
Some figures, often quoted, may be recalled here. The U.S.-figures as presented e.g. by Hollister show a
steady rise up to the early 70ies and then (since 1973) a steady fall, which has continued into the eighties. (Figure
3a).
In 1981 Blaha and Bruckmann presented figures for several European countries, stressing at the same time
the difficulty of gathering reliable figures. With their reservations on the reliability of these figures they are
reproduced here. Their figures have been drawn as a graph (Figure 3b). The figures can be found in the Annex
Table 3(i).
A similar time course of the benzodiazepine consumption as in the U.S. has been found in Finland, the
highest peak being reached in 1970 i.e. earlier than in the U.S., while in other European countries there is on the
whole stabilization of consumption figures in the seventies. Czechoslovakia and Iceland which are still climbing,
have the lowest and the highest absolute consumption among these countries.
Consumption figures for developing countries and Australia have been gathered in the course of the IM-
p ACT study, tables are given in the Annex. (Table 3(ii)).
A comparison between Indonesia and Malaysia shows that absolute figures are roughly 100 times lower in
Indonesia. Taking into account the population number they may be more than 1000 times lower per population
head in Indonesia. Indonesia shows a rather stable consumption over the investigated 3 years, while in Malaysia
there is a marked downward trend, the 1981 figures being at least 50070 lower than the 1978 figures for the more
important products.
Hong Kong's figures of consumption differs in their trend from one drug to another. The total consump-
tion seems rather stable, probably with a slight upward trend since 1978. Taking into account the total popula-
tion, Hong Kong's consumption is at least 10 times higher than Malaysia's (and by that about 10,000 times
higher than Indonesia's). Singapore shows a definite diminution of benzodiazepine consumption from 1978 to
1981, the latter figures being about 50% of the former. In the Philippines there may be on the whole a slight up-
ward trend of consumption. Australia shows a marked increase from 1967/7 to 1980/1, mainly due to the doubl-
ing of the consumption of oxazepam, which in this country is clearly the leading market product. Taking into ac-
count DDD the Australian consumption may be around 50 times higher than in Malaysia.
A comparison of consumption figures of Australia (Figure 3c) with those of Malaysia (Figure 3d) shows a
sharp contrast. While the Australian total consumption figure is climbing the Malaysian figures are coming
down, inspite of the fact that no overall special control for benzodiazepines has been instituted in Malaysia. This
fall of consumption figures has to be attributed to an educational campaign for critical prescription practices
among Malaysian prescribers.
This play with numbers raises more questions than it answers. It has a very limited value as we do not know
to what segment of the population benzodiazepines are available. Thorough drug utilisation studies would be
needed, along with epidemiological studies of morbidity prevalence and doctors' prescribing habits.
Based on these consumption figures alone and comparing them with those from U.S. and Europe there is
no support for the hypothesis of overconsumption in these developing countries.
To answer the question whether there is overconsumption the fact that consumption figures are high is not
a sufficient basis. These figures must be seen in relation with the number of people who are in need of the drug.
This second field is still less explored than the consumption in absolute numbers. Prevalence of psychic distur-
bances. aJlxiety itt panicular, and the usual means of coping with them is known only in a very imprecise man-
ner. Some epidemiological studies have been undertaken starting mainly from the U.S.
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FIGURE 3a: Trend in Prescription for Antianxiety Drugs Adapted frum Hollister
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FIGURE 3d: Total Use of Benzodiazepines in Terms of
DDD per year - Penang, Malaysia
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In 1973 when benzodiazepine consumption was peaking in the U.S. the National Institute of Mental
Health sponsored a survey to get more precise data about how antianxiety drugs were used. In a large random
sample of adults in the U.S. it was found (Pa,rry, Balter, Mellinger, et. aI., 1973) that about 15070 had taken at
least one dose of an antianxiety drug, and about 6010 had taken them for (at least) as long as one month. There
was, however, no means of checking whether this extent of use was appropriate or not. So the study was extend-
ed into nine countries of Europe. This showed (Balter et. aI., 1974) that Belgium and France were highest, Spain
lowest and U.S. the average in sedative-hypnotic consumption. The numbers however show a rather narrow
range, neither "any use" nor "regular use" numbers scattering by a factor bigger than 2 among highest and
lowest consumption.
A comparison of these figures with the few data obtained from developing country presents several major
difficulties. But also by themselves these figures show just a similarity between U.S. and some European coun-
tries. They do not say anything on the justification of the benzodiazepine medication. Here epidemiological
studies on the incidence of emotional disorders come in.
Epidemiological evidence points to a point prevalence of about 15% of the general adult population hav-
ing mental health and severe emotional problems, the overall prevalence being at least 20% (Regier et. aI., 1978;
Pardes, 1979; Kohn and White, 1976; Dohrenwend, et. al.,). In patient populations similar or higher rates are
found (Shepherd, et. al., 1966).
It was again the Balter, Mellinger, group who undertook a survey on the incidence of psychic distress and
life crisis in the U.S. population, these being main indications for the prescription of anxiolytic drugs. At the
same time alcohol consumption in this population was investigated. This investigation (Mellinger, BaIter et.al.,
1978) showed that most of the regular users of psychotherapeutic drugs reported some psychic distress or life
crisis.
Table 3a: Sedative-Hypnotic Drug Use in U.S. and Europe
adapted from Hollister
Country Percentage of Respondants
Any Use Regular Use
Belgium 17 8
France 17 7
Sweden 15 6
Denmark 15 8
U.S.A. 15 6
West Germany 14 6
Great Britain 14 8
Netherlands 13 8
Italy 11 3
Spain 10 4
The more serious they were the greater was the fraction of patients treated with drugs. However, even of
those reporting a high level of emotional distress and of life crisis only 35% of the women and 21 % of the men
had used any psychoactive medication at anytime in the previous year. It is interesting to see that alcohol use in-
creases and is three to five times more frequent than regular use of psychotherapeutic drugs. In June 1981 Mell-
inger reported at a meeting in Milan, a follow-up done in 1979 of the quoted study. The follow-up confirmed the
earlier views that "the prescription practices of physicians, as well as the attitudes and drug using behaviour of
the general public, tends to be moderate and conservative". This is confirmed by other studies of the frequency
with which tranquillizers are used. Kohn and White (1976) have established a point prevalence of use of about
16
Table 3b: Psychotherapeutic Drug and Alcohol Use in Relation to Psychic
Distress and Life Crisis adapted from Hollister
Any drug use Regular drug Alcohol use Total persons
past yr. (070) use (070) (070 ) (070)
Psychic Distress
Low 9 3 34 1126
Medium 18 4 33 688
High 31 13 37 714
Life Crisis
Low 11 3 28 647
Medium 1<5 5 34 1061
High 21 8 41 820
2070 of the adult population and an annual prevalence of just under 15070 for the U.S. and several other countries.
Studies by Uhlenhuth et. ai., (1978) and by Hesbacher et. ai., (1976) examining how well treatment was fit-
ted to the treated illness point in the same direction that physicians do not unaccountably prescribe
psychotherapeutic medication for emotionally healthy patients.
Allgulander from the Karolinska Institute found no evidence for over-prescription of benzodiazepines in
Sweden in 1978.
These painstaking (and costly) studies come from highly industrialized countries. Similar data have not yet
been gath'ered for developing countries. However, from recent WHO sponsored studies (Johnson 1976; Harding
et. ai., 1980; Busnello 1980) the (tentative) conclusion has to be drawn that there is not conspicuous difference in
prevalence of emotional disturbances from jndustrialized countries. Consumption figures for benzodiazepines
are however, very much lower per population head. Several factors may be hypothetically involved to explain
these facts. First only a minority of the developing countries' population may have access to benzodiazepines
(and other drugs). Second, financial aspects may be important. At first glance drug consumption (overall)
roughly parallels national income. Third, these countries may have other (non-drug) sources to deal with emo-
tional disorders (traditional healers, witch doctors). Fourth, there may be underprescription and underconsump-
tion in relation to the total population, while some small segments of the population may get adequate or even
exaggerated amounts of psychotherapeutic drugs. Only indepth drug utilisation studies will allow to answer
these questions in the future.
Some of the criticisms that are current (but probably not founded on sound facts) and have given rise to
the assumption that benzodiazepines are overused should be mentioned here. The recent book of Ruth
Cooperstock (1982), "The Effects of Tranquillization: Benzodiazepine Use in Canada" may serve as an exam-
ple. She argues that many stress situations derive from the social settings in which the patient is living, and
recommends that the right answer would be an alteration of the social condition, not a tranquillizer drug. She
may be right in theory but the practicability for the physician who is confronted with the problem may be ques-
tionable. There is no doubt however, that here is a large field for education of physicians on how to deal with
psychological disturbances. Physical exercise was recommended by Hollister as an alternative to anxiolytic
drugs. Alternatives have to be weighed carefully; alcohol would not seem to be a good answer.
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4. BENZODIAZEPINES - ABUSE LIABILITY AND ACTUAL ABUSE
Practically since the introduction of the benzodiazepines it was known that they can produce physical
dependence. HOLLISTER, in 1961, published that by giving psychotic patients over months very high doses of
chlordiazepoxide and then stnpping treatment suddenly, he was able to produce a withdrawal syndrome, two of
the eleven patients having epileptic fits.
So the scientific community was aware of the possibility of physical dependence with protracted high
doses. However, it was mainly in the second half of the seventies that attention was focussed on abuse and
dependence problems connected with benzodiazepines. Surely the public media had an influence so that this
aspect was brought to attention, be it for the better or worse.
One of the main difficulti~s in resolving this question was stressed in the report of the 5th WHO REVIEW
COMMITTEE ON PSYCHOTROPIC DRUGS (Nov. 1981). It is the fact that compared to the wealth of
anecodotal unsubstantiated evidence there are only scarce hard scientific data to form a decision basis, as the
report states.
" ... there is in most countries a lack of adequate information about the way in which and the extent to
which drugs are used and misused".
As a consequence of this the IMPACT study was carried out in order to get more precise data at least on
the numbers of abuse cases in a few countries.
First a question of nomenclature should be clarified. Abuse and dependence are by no means synonymous.
Abuse should be defined as use outside prescribed therapy, or use in higher doses or for a longer time than
prescribed. Even here arise difficulties. Is a Bangkok taxi driver who loses a days work in going to an ambulatory
and gets a prescription for a minor tranquillizer abusing the substance if he buys a second package without a se-
cond p~scription because the first package was beneficial? How far can an attempt to self-medication be
qualified' as abuse? How should the patient be classified who gets over a prolonged period of time report
prescription for his tranquillizer from the receptionist of his doctor without the latter seeing him again, as it
seems to happen frequently in the U.K. Marks, (1981) calculated, out of several studies, a mean of 50010, and the
U.K. is probably not the only country where this happens - it is just in the U.K. that these studies have been
done.
True dependence, physical and psychological, is known to occur, but the frequency of this phenomenon is
debated. A first distinction is necessary, primary benzodiazepines dependence and benzodiazepines dependence
within the frame of polydrug abuse.
In polydrug abuse numerous cases seem to be known. Many of them can be qualified as iatrogenic; this is
the patient who was withdrawn from another drug with the help of a benzodiazepine and then became dependent
on benzodiazepine. Benzodiazepine were for a number of years recommended in alcohol withdrawal, and also
found rather safe in this indicator (Le. Rothstein, Kryspin, 1976; Exner, 1975). However, there are enough
authors who would not agree with this (e.g. D. Smith, 1981) so that the validity of benzodiazepines in alcohol
withdrawal seems questionable. The same holds true for withdrawal from opiates, particularly heroin. But it
must also be seen that this may often be, from a drug stand point, a no win situation. Well controlled prospective
studies on this subject are lacking so far. In order to avoid difficulties for their benzodiazepines some drug
manufacturers go as far as to warn against the use of benzodiazepines in detoxification of dependence patients.
It may be questioned whether this is in their own or in societies interest.
One consequence that must be drawn from this is that prescription of a benzodiazepine to a dependence
prone individual (that is an individual who has already a drug or alcohol problem, the role of smoking having
not yet been elucidated) must be very carefully weighed by the prescribing physician. Will the prescription bring
a benefit that is worth the risk of dependence? Treatment should be closely monitored and terminated as early as
possible. To evaluate the risk it should be routine to take a careful drug history of the patient. However, neither
this nor the close monitoring is routine - far from it.
It is safe to say that in the therapeutic setting dependence is rare. Its danger is increased with higher dose
and with prolonged treatment. Pure benzodiazepine dependence stemming from the therapeutic situation has
been looked for by several authors in prospective studies and not found (Le. Balmer, et. aI., 1981). However, as
its incidence is rare it would be surprising to find them is such studies. Few data are available to calculate some
sort of incidence of pure benzodiazepine dependence. The admission figures of the THANYARAK hospital in
Bangkok illustrates the problem - where less than 1070 of the addiction admissions were for benzodiazepines.
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TABLE 4(a)
15366 Total Admissions 100070
14977 Narcotics 97.47070
277 Analgesics 1.48070
119 Benzodiazepines 0.77070
25 Other Sedative-Hypnotics 0.160"/0
18 Volatile Substances 0.12070
This table draws also attention to the fact that analgesics are more often abused than benzodiazepines.
There are data from Thailand that salicylic acid preparations are the most commonly abused drugs among those
who are not in the dangerous drug register. The use does not always seem to be rational. It is said that about 70(}!0
of the hill tribe people mix opium with salicylic acid preparations before smoking.
Similar figures on the relative abuse potential for analgesics and benzodiazepines have been reported from
Switzerland. Kielholz (1968) compared the dependence producing potential of different substances. Allocating
analgesics a risk quotient of 1, hypnotics were ranked 2.7, cerebral stimulants of the amine group 3.8 and tran-
quillizers 0.2. Prescott (1975) quotes that in New England there was a striking correlation in high-school children
between the use of aspirin and the taking of non-medical psychoactive drugs such as marijuana, hallucinogens,
amphetamines and barbiturates. It has to be borne in mind that salicylates have a much higher toxicity than ben
zodiazepines (see Social Issues).
Another group of substances that is increasingly abused are the volatiles. In Mexico volatile substance
abuse has become more frequent than the abuse of tranquillizers (Hughes et. aI., 1980). Recent reports from
Singapore indicate that there have been a few cases of volatile abuse including olle that culminated in a lethal
overdose.
To our knowledge the only careful and extensive review of tranquillizer abuse was done by Ladewig
(1981) in Switzerland. He interviewed all practicing physicians of his country by questionnaire concerning use of
benzodiazepines, long term treatment (more than 10 weeks) and observations of inappropriate use during the
last 5 years. He received replies from 72.9070 of the questioned physicians. All those who reported observations
of abuse were contacted by telephone and interviewed following a structured questionnaire. He found 180 pa-
tients for the 5 years period that seemed to be isolated benzodiazepines abuse. In this group there were positive
and negative consequences of abuse. Positive consequences were ability to work and social stabilization.
Negative consequences were irritability, increased fatigability and loss of interest. "In both the "switch-over"
group and in those patients misusing benzodiazepines in combination with alcohol, hard drugs or other
psychotropic drugs, significantly more negative consequences are listed. Particular mention is made of the
markedly increased risk of accidents in traffic and at work".
Ladewig calculated a risk of two dependence cases per 100,000 prescriptions for benzodiazepines; for the
five most frequently used benzodiazepines (only for these five such a calculation was meaningful) the incidence
of dependence cases per 100,000 prescription was scattered over a very narrow range, 1.6 to 2.. 1. *"It was not
possible to identify any increase in the inappropriate use of a particular compound. Among those found to be
misused were both drugs with short half-life and those with long half-life, so that, from the epidemiological
point of view, it is not possible to establish a connection between half-life and abuse risk".
It must be stressed that Ladewig is strictly speaking of "abuse". It can be assumed that quite a portion 0 f
these patients were also dependent. To find out this portion it would have been necessary to stop the ben-
zodiazepine treatment abruptly and see what happened. This had been done on some cases by the treating physi-
cian as Ladewig reports .. Typical or atypical withdrawal symptoms had been seen in 48 patients and no
withdrawal symptoms in 55. For 77 cases no data were available.
Within the frame of polydrug abuse (alcohol included), one should distinguish drug experimenters from
habitual drug abusers. Here even less is known about incidence and frequencies. In the Ladewig study th"
number of the polydmg abuser amounts to 254. However, in many studies the proportion of the polydrug
abusers with benzodiazepines is much higher than 2 (approxim'ate figure of Ladewig's study).
• The five most frequently used benzodiazepines in Switzerland are: bromazepam, diazepam, f]unitrazepam, lorazepam, oxazepam.
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What is the benzodiazepine,'s role in the field of polydrug abuse? Already here opinion is not unanimous.
In the industrialized countries the benzodiazepines seem rarely to be a drug of primary abuse. David Smith
(1981) is unequivocal in his statement, that benzodiazepines are not "primary drugs of abuse". Claims to the
contrary (Woody, Patch, both quoted in Greenblatt and'Shader) have not been substantiated by reliable
documentation (Greenblatt and Shader, 1981). However, many dependents on heroin and amphetamines carry
benzodiazepines in their pockets to get down from a bad trip that has provoked an anxiety state. How often they
use this medication is a matter of guess. Urine analysis has given contradictory results. PRIMM (1981) reported
in the U.S. FDA expert panel a very low incidence of benzodiazepine finding in random urine samples of a
population of heroin addicts in Harlem. However, Poshychinda (1982) has recently reported that in Thailand
diazepam use among the opiate dependents changed its role from being the supportive drug suppressing
withdrawal signs and symptoms to being the synergistic drug used in combination with the opiate to potentiate
the effects. 1.4070 of the opium dependents and 3.5070 of the heroin dependents were using the opiates in com-
bination with diazepam. In amphetamine dependents the use of diazepam was even higher (around 20%).
However, Poshychinda states at the same time, that the current data and information on diazepam abuse and
dependence "by far fall short of presenting a clear pattern of the status of the situation".
The same author (1979) warns against "inappropriate and untimely control of a drug" because this "can
actually lead to the aggravation of the drug dependence problem as evident in this country when opium was
replaced by heroin". Here again more data would be needed to evaluate the situation.
What do the data from other sources, including the IMPACT study, show for illicit drug traffic and
~?
Article 4(b) of the 1971 Convention on Psychotropic Substances requires "that there is sufficient evidence
that the substance is being or likely to be abused ... warranting the placing of the substance under international
control" .
-'
Traditionally the type of evidence that has been reviewed included not only public health problems, extent
of abuse, etc. but also evidence of illicit traffic in that substance. This approach is in consonance and
acknowledgement of the theory that illicit supply and illicit demand are intimately interlinked. The question
whether illi'rit supply induces illicit demand or whether illicit demand stimulates illicit availability has been
debated for many decades, and undoubtedly this will continue for several years in the future.
In keeping with the accepted practice, existing data of illicit availability and extent of abuse was reviewed.
Country Reports to the United Nation Secretary-General,as well as Reports to Interpol were used as the infor-
mation base.
ILLICIT TRAFFIC
Thirty-three countries reported the existence of illicit traffic with the benzodiazepines. Since the countries
reporting are scattered throughout the world, it would be appropriate to conclude that illicit traffic in ben-
zodiazepines exists in all regions of the world (Table 4(i), see Annex).
Of the 27 benzodiazepine substances reviewed, evidence of illicit traffic was reported for nineteen of these
substances for the period 1979-1981. The benzodiazepine substances for which no evidence of illicit traffic was
presented included alprazolam, camazepam, fludiazepam, nordiazepam, oxazolam, pinazepam, tetrazepam and
halazepam. Table 4(i), Annex shows the analysis of various benzodiazepine substances fOllnrl in illicit drug traf-
fic by the various countries. Careful study of the data indicated that those benzodiazepine substances not
reported or infrequently reported correlated very closely with those benzodiazepines which were less widely
marketed globally.
An attempt was made to quantify the amount of the various benzodiazepines intercepted in the illicit drug
traffic. Nineteen countries reported to the United Nations amounts of benzodiazepine seized in illicit drug traf-
fic. Table 4(ii), Annex provides the analysis. Since the seizures were reported in various manners i.e. in weight,
tablets/capsules or dosage units, it was not possible to do a more indepth analysis of reported consumption, im-
portation and amount detected in illicit traffic. Actual seizure data was available for 17 benzodiazepine
substances. The amounts seized varied widely and again it was apparent that the more widely the substances were
marketed, the greater was the quantities that were likely to be intercepted in illicit drug traffic.
ABUSE DATA
Based on data reported to the United Nations for 1981/1982 it was found that twenty-two out of fifty-
seven countries indicated the existence of benzodiazepine abuse (Table 4(iii) , Annex). Interestingly only 16 of the
57 involved countries reported that they were experiencing a benzodiazepine problem which was causing public
health concern. Twenty countries, including six countries who reported existence of benzodiazepine substances
being abuse do not present any public health problems. Table 4(iv) in the Annex presents the relevant data.
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An analysis of the reported abuse data with the various benzodiazepine substances was carried out (Table
4(iv), Annex). Here it was noted that nineteen benzodiazepine substances were reported as being abused. In-
terestinglY, it was noted that three substances - alprazolam, camazepam and fludiazepam - for which no illicit
traffic data was reported were being reported to be abused. Similarly three substances for which the existences of
illicit traffic was reported did not have abuse indications.
Combining both the illicit traffic information and the abuse indication, one reaches the general conclusion
that evidence existed which associated 22 out of the 27 benzodiazepine substances with illegal availability and/or
abuse.
An attempt to quantify the extent and severity of the benzodiazepine problem was made. It was obvious
from the very beginning that it was close to impossible to assess the exact (actual) extent of benzodiazepine
abuse. Only nine countries were in a position to give a "head count" - where benzodiazepine abuse was the
primary factor. Table 4(v) shown in the Annex provides a breakdown of actual cases of abusers and the type of
benzodiazepine substance abused. A total of 1438 cases were reported by the nine countries, and these involved
eleven benzodiazepine substances. Since it is acknowledged that data on actual benzodiazepine abuse is not only
scanty and that specific diagnosis of benzodiazepine dependence is extremely complex, great caution is ad-
vocated in the use and interpretation of this data. From a methodological view point, it would be accurate to
state that the reporting here may well not represent the actual extent of abuse. However, one could conclude that
benzodiazepine substances are being abused and obviously have the potential to be abused. From this data one
cannot draw an immediate conclusion that benzodiazepines on their own, are causing a significant social and
public health problem. What is needed is more precise studies, particularly epidemiological and clinical, to deter-
mine the real extent of abuse and the associated problems.
An attempt was made to examine the extent to which benzodiazepine abuse contributed to the na-
tional/international drug abuse problem. Data reported primarily to the United Nations, as well as other sources
were compiled as shown in Table 4(vi). This table compares for the different countries the number of persons ar-
rested for drug abuse, with number of persons arrested for opiate abuse and reported cases of benzodiazepine
abuse. Out of 85 countries that were reviewed for the drug abuse situation in 1980, it was noted that only eleven
countries did not report the existence of a drug abuse problem. German Federal Republic, Canada, Australia,
Japan, South Africa reported drug related arrests of over 20,000 for 1980. The total number of drug related ar-
rests amounted to 3,344,110. Of this population 32,073 were arrested because of association with opiate abuse
and 346 with benzodiazepine abuse.
The data tend to indicate that benzodiazepine abuse is minor compared to the general drug abuse problem
or even opiate abuse. This is partially accurate since several countries stressed that benzodiazepine abuse was a
secondary problem component to the problems associated with narcotic drugs. However, it must also be ap-
preciated that the absence or insignificant reporting of benzodiazepine abuse, in almost all countries may be a
bias as most nations have developed good monitoring systems for narcotic drugs specifically but not for ben-
zodiazepines. The occurence of benzodiazepine abuse tends to be reported peripherally through the narcotic
reporting systems.
In view of the inadequacy of data, it is extremely difficult to arrive at any conclusive statements on the
abuse of benzodiazepines. It should be pointed out here that at least in two countries, Cyprus and Kuwait, ben-
zodiazepine abuse represents a significant proportion of the drug abuse problem and is equivalent to if not
greater than, in one country, the opiate abuse problem, though the incidence is small. Here again one is drawn to
the general conclusion that benzodiazepine substances cause or possess the potential to cause an abuse problem.
The difficulty that exists, is in determining whether they are causing social and public health problems to an ex-
tent that it is affecting the social fabric of society. This is one of the importilnt questions that the UN Commi~-·
sion must take into consideration in its decision making process.
In this context the Commentary on the Convention on Psychotropic Substances is of interest; it reads
(page 47, para 8.).
"If the substance is abused or likely to be abuse in more than one country so as to
constitute a public health and social problem in those countries, the problem is "in-
ternational", but this international character alone does not warrant "international
control". What is required is that controls of the 1971 Convention are suitable to
solve or at least to alleviate the problem ... ".
The Commission will have to consider whether these requirements for international control are met by the
data available for benzodiazepines. These have been decisions on similar issues previously. One such substance
that has been brought to the attention of the Commission as a problem drug was pentazozine. Several countries
since about 1980 have reported a significant abuse by its nationals. During the 1982 Session of the Commission,
the Commission in concurrence with WHO recommendation did not schedule pentazozine under the 1961 Single
Convention in spite of the fact that the substance had demonstrated evidence of dependence liability and signifi-
cant data of abuse.
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5. BENZODIAZEPINES - PUBLIC HEALTH AND SOCIAL ISSUES
In view of Article 2 in the 197 I Convention, mentioning public health and social problems expressedly for
the consideration of scheduling substances, these issues will be considered here.
Mortality from overdosage of benzodiazepines is extremely rare. Finkle et. aI., (1979) surveyed all drug in-
duced deaths covering a total population of 79 million people in U.S. and Canada. Among 1239 fatal cases in-
volving diazepam, only two could be attributed to diazepam itself. Similar results were reported by Prescott
from Edinburgh in 198 I, his main conclusion being that "death from benzodiazepam poisoning alone is ex-
tremely rare, ... in only one case in 8000 could death reasonably be attributed directly to benzodiazepine poison-
ing .... Since they have replaced the barbiturates the management of sedative-hypnotic poisoning has been
transformed with much less frequent need for the full resources of intensive care".
This is set into perspective by the comparison with aspirin. This drug is "most commonly involved in
paedeatric poisoning in the USA and some 500 ct.ildren die there annually from this cause" (Prescott, 1975).
The incidence of overdosage of psychoactive drugs is largely related to the general levels of medical use and
of availability. Alcohol is the most often used psychoactive substance in most societies, and also the most often
abused. The great number of cases of benzodiazepine overdosage cases seems proportional to their wide
therapeutic use. This is also confirmed by the Dawn data as presented by Rootman and Hughes (1980). Among
the estimated emergency room visits monitored by the Dawn system, diazepam is top of the benzodiazepines and
ranks high among the substances mentioned. However Rootman and Hughes have already added to the Dawn -
data prescription information "to put these statistics in perspective". If viewed in relation with the prescription
figures these numbers show indeed a different aspect. Diazepam comes down to the level of non-dependence
producing substances like amitriptylil1e and chlorpromazine, methaqualone standing out; the same holds true
when the emergency room figures are related to the total number of pills prescribed.
TABLE S(a)
Emergency Room Admissions - adapted from Rootman et. aI.,
per 1000 per 100,000
prescription tablet prescribed
Diazepam 0.95 2.47
Flurazepam 0.90 2.86
Chlordiazepoxide 0.61 1.01
Amitriptyline 0.85 1.54
Chlorpromazine 1.28 2.25
Pentobarbital 1.70 3.54
Methaqualone 4.15 11.00
Another indicator which would support the hypothesis that availability is an important, if not decisive fac-
tor; is that diazepam mentions have shown a consistent downward trend in Dawn mentions over the last few
years, in parallel to the consistent decline of prescription its frequency.
Finally it must be seen clearly that Dawn data represent acute intoxications; they mirror abuse of drugs
mainly, with and only in much smaller percentage dependence could be found as a motivation for drug taking.
With all the "caveats" that are inherent in the Dawn recording its data have to be interpreted with great caution.
It might be added here that the number of suicidal attempts has not be influenced by the replacement of
barbiturates by benzodiazepines. However the success rate of such attempts with benzodiazepines is certainly
much lower than with barbiturates and the treatment cost will be lower too, because as Prescott (and others)
states much less intensive care facilities are needed. The symptomatology of benzodiazepine intoxications alone
even in high overdosage is usually not life threatening, nor do they produce systemic toxicological effects in
acute overdose or in chronic use or abuse (see Toxicology section).
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As with all CNS depressant drugs the combined effect of a benzodiazepine together with akoholl:an result
in an increased risk to the patient. This has led to the warning against taking benzodiazepines and consuming
alcoholic beverages at the same time. However Prescott (1982) has encountered "drivers of double decker buses.
of heavy goods vehicles and even the operator of a very large crane who stated that they had been prescr;bed ben-
zodiazepines without any warning and restrictions".
This is of special importance in traffic safety. This highly complex issue is far from clear. It seems rather
certain from laboratory studies that psychoactive drugs can produce impairment of performance even at a
therapeutic dose (Linnoila, 1978; Nicholson, 1982). However, none of these laboratory parameters has been
validated as a predictor of impaired (or unimpaired) traffic safety, nor are there, at present, epidemiological
studies that establish the role benzodiazepines play in road accidents (Laudaner, 1981). This has however re-
mained a controversial issue, as has the validity of predicting traffic safety from laboratory tests and from ben-
zediazepine blood levels. Certainly more research is needed in this field. Most experts however agree, that
alcohol is a more important factor than benzodiazepines, and that the combination of the two should be avoided
by all means when driving. All the more serious is the statement of Prescott quoted above; still better informa-
tion on this issue to and by all physicians prescribing a benzodiazepine is desirable. A reservation has further to
be made on studies of nonl1al subjects under the influence of benzodiazepines; anxious or sleepless patients
would be the valid subject selection, with or without benzodiazepine treatment.
The studies most needed in this field are of epidemiological nature, and their difficulties have been stressed
in a recent WHO report (Techn. Rep. Series 656). In view of the important toll traffic accidents demand in
human suffering and in financial losses this is an issue of high priority.
Within the social issues of benzodiazepines use and abuse, referral is made to the chapter on therapeutic
use where studies of some social effects have been reported.
There is no reliable evidence that benzodiazepine use leads to criminal behaviour, (Tinklenberg, et. aI.,
1981). Thefts of benzodiazepines, with subsequent resale through normal channels have been reported. This type
of criminal activity is, however, nor limited to benzodiazepines, but concerns many other pharmaceuticals, in-
cluding antibiotics. Prescott's (1982) statement about benzodiazepines may be quoted here: "They are not
"fun" drugs .... In Edinburgh drug takers and pushers often break into chemists' shops (drug stores). They are
very discriminating and clear out all the narcotics, barbiturates, methaqualone and amphetamines but leave the
benzodiazepines behind". Another factor to be taken into account in the evaluation of psychoactive substances
is their potential mode of spread (WHO Techn. Report Series 407). There is no evidence that benzodiazepine
users act as agents for spread of misuse of these drugs. Benzodiazepines have a low preference rating among
drug abusers. However according to some reports benzodiazepines besides many other substances seem to, be
popular among group experimenters. No data are available on the quantitative importance of this, nor are there
data to assess their dependence potential in these circumstances.
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6. LEGAL IMPLICATIONS OF SCHEDULING PSYCHOACTIVE SUBSTANCES
IN THE 1971 CONVENTION
RATIONALE AND MAJOR AIMS OF THE CONVENTION
The Convention on Psychotropic Substances is an international and multilateral agreement designed to
prevent and combat the abuse of any psychoactive substance, natural or synthetic, that fulfills the criteria of a
psychotropic substance as defined by the 1971 Convention. The major aims of the Psychotropic Convention arc
to control the production, exportation and importation of such substances and to restrict their use to medical
and scientific purposes through a system of coordinated national and international measures. They are in essence
conceived after the model of the 1961 Single Convention on Narcotic Substances.
Drugs are classified into four schedules according to actual or potential abuse, and therapeutic usefulness.
The decision to schedule has also to take into account some rather vague general criteria ("economic, social,
legal, administrative and other factors") referred to in Artide 2.
In its preamble the Convention refers to "the public health and social problems which result from the
abuse of certain psychotropic substances". The parties are "determined to prevent and combat abuse of such
substances and the illicit traffic to which it gives rise". They recognize "that the use of psychotropic substances
for medical and scientific purposes is indispensable and that their availability for such purposes should not be
unduly restricted". The underlying objective of the Convention is to minimize availability of psychotropic
substances for abuse without unduly restricting their availability for legitimate therapeutic purposes. This is a
basic difference to the 1961 Convention.
The Convention entered-into force on 16th August, 1976, that is, when 40 states had ratified it according to
Article 26. As of early 1981,68 nations out of 152 UN member states have ratified the Psychotropic Convention
whereas 113 nations have ratified the Single Convention. There still seems to be considerable reluctance on the
part of a number of nations, being drug manufacturing and drug importing, to ratify this treaty.
-..
PROBLEMS OF SCHEDULING CRITERIA AND TERMINOLOGY
The treaty itself does not contain guidelines to indicate on which schedule a drug should be controlled. The
decision to employ only general criteria stems from the fact that WHO's determinative role was restricted to the
assessment of medical and scientific matters (Article 2, Section 5 of Convention). The generality of the criteria
however may lead to ambiguities. The interpretation of scheduling criteria may be arbitrary, consequently the
scope of control might be extended or modified in unexpected ways (Report of the International Working Group
on the Convention on Psychotropic Substances, 1971, September 8-12, 1982, Addiction Research Foundation,
Toronto, Canada - Toronto-Report).
Finally terminologies of the Conventions have been subject to criticism. In particular, there is a discrepan-
cy between the terminology of the Conventions and of medical and pharmaceutical literature. The Conventions
do not adequately present scientific criteria of classification for different dependence types. Also the lines are
not clearly drawn between drug misuse, abuse and dependence. If control is to be international in nature rather
than national, then it would be important to clarify these definitions. Furthermore, the 1971 Convention does
not address the problem of drug overuse by inadequate prescription.
ADVANTAGES AND DISADVANTAGES OF THE CONVENTION
The needfor control of psychoactive substances has been recognized by many nations since about 30 years.
However, the need for an international treaty has a shorter history and fewer suppo"rters. Many nations felt -
and still feel - that national control systems are sufficient and more adequate to deal with these problems. Any
legislation concerning the complex field of drug abuse must fit within the general framework of national public
health policy.
International treaties at the global level result from a compromise between largely diverging opinions bet-
ween different states of different cultural and socio-eco'1omicbackground on objectives to read: ,1lld measures
to appiy. However such treaties are only one component affecting prevention, education, treatment, rehabilita-
tion, reintegration and legal measures at the national level. The implementation of appropriate measures against
substance abuse falls primarily in the sphere of national sovereignty.
The 1971 Convention brought a major advance over previous international legislation since it took into ac-
count the balance of social benefit, social and medical cost, and cost of legislation. Ideally the advantages in
joining the Convention consist in a shared responsibility for the international solution of a difficult problem.
The real value of the Convention however depends on the care with which States transform and implement the
international treaty in their national legislation. Under these conditions, the following major benefits can result
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for a country from ratifying the Convention:-
The Convention assists governments to prevent easy availability of Schedule I substances which
have limited or no medical use (Toronto-Report). The existence of an international treaty provides
some form of moral pressure on government.
Implementation of the control measures required by the Convention may necessitate the revision
and updating of the national drug control mechanisms (Toronto-Report).
- The system of repon ing has proved to be useful not only as a control measure but as a tool for
policy-making.
- Article 13 allows a country to notify all other parties through the Secretary General that it pro-
hibits the import of (;l substance in Schedules II-IV. But Article 13 cannot prohibit the trans-
shipment of substances through third countries which are not parties to the Convention. The
benefits of Article 13 can therefore easily be annihilated until the acceptance of the Convention
has become worldwide.
Some of the criticisms that can Ile addressed to the Convention are implicit in the above considerations.
There are however further limitations.
International treaties offer the potential for strengthening national legislation. If such legislation, e.g.
availability on prescription only, is not in existence, or not implemented, international treaties will have little
positive impact. New or additional control mechanisms can be very costly and require supplementary ad-
ministrative work. However many developing countries are handicapped by the very limited number of physi-
cians, pharmacists and pharmacies in their countries. They do not have enough professionals to assure an ap-
propriate drug distribution network.
Some developing countries are not in a position to comply with prescription obligations as required by the
Convention. The strict fulfilment of these obligations could therefore lead to the restricted availability of impor-
tant therapeutic agents and hinder the medication of a relatively significant proportion of the countries' popula-
tion (Toronto-Report, 1981).
Morever the adverse effects of regulation on the availability of medically needed drug in different develop-
ing countries was commented upon by different authors (Soueif, 1981; Supnet, 1980; Zarco and Almonte, 1977;
Gamez, 1982; Comlavi, 1980).
Another undesirable effect of control can be the development of black markets in drugs and the
criminalization of users (John C. Kramer). In this context it has to be stressed that the Convention does not en-
visage the problems of imitation and counterfeits and it does not affect street level abuse. Therefore the Conven-
tion is unable to deal with illicit trafficking of licitly or illicitly produced substances. Another fear seems to be
that if larger numbers of substances are brought under control, development of new drugs may be hindered
(Psychotropic Substances and Their International Control, Toronto 1981).
Finally inadequate availability as a consequence of international control can cause many people to switch
to undesirable alternatives, e.g. alcohol. The WHO Expert Committee Report on the Assessment of Public
Health and Social Problems asso~iated with the use of psychotropic drugs noted that the net result of placing a
drug under control may be positive, neutral or negative, depending in part, on the substitution of other drugs. If
the controlled drug is replaced by another of equal or more deleterious effects the goal is not attained.
CONCLUSIONS
Severai quesiionsabout the benefits of the Convention on Psychotropic Substances as an effective
meansto combat drug abuse especially in developing countries remain unanswered.
In particular, Article 13 does not affect illicit trade nor does it cover the problems of counterfeit and
falsification. The scheduling of substances hampers licit trade and might have negative effects on the availability
for therapeutic use, especially in developing countries.
As there is often no uniform pattern of abuse for individual substances throughout the world, local and
regional aspects have to be taken into consideration. It must be carefully assessed whether there is a need for in-
ternational control as opposed to national or regional measures. Some authors point out that strategies pattern-
ed after western models have been found to be ineffective and counter-productive in developing countries.
Most scientific information on use and abuse patterns of psychotropic and other psychoactive substances
has been gathered in industrialis~d countries. For the developing countries information is scarce and mostly
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anecdotal. Reliable data on use and abuse patterns as well as on level and/effects of control in developed as well
as developing countries should form the decision basis for measures of international control.
The international substance' control system should not be burdened by the control of substances which
constitute mainly a local or regional problem. The problems vary from one country to another and it is a com-
plex and difficult process to shift out from national experiences the factors relevant for the common benefit of
the international community. Only such substances or groups of substances should be put under international
control the abuse of which has a significant negative impact on the state of public health at the international
level. However, from a prev( ntive consideration, substances that have reliable data as causing social and public
health problems, though not global in proportion should be evaluated for control.
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7. BENZODIAZEPINES - ASSESSMENT OF THE IMPACT OF SCHEDULING
Many countries have expressed concern over the past few years about the effectiveness of the 1971 Conven-
tion on Psychotropic Substances as well as the problems associated with drugs scheduled under this Convention.
The report of the International Working Group on the Convention on Psychotropic Substances, - September
8-12, 1981, Addiction Research Foundation, Toronto, Canada, reviewed many of these concerns. This same
concern was reexpressed during previous Commission meetings in particular the last special session of the United
Nations Commission on Narcotic Drugs, during the debate on proposals for scheduling substances under inter-
national treaties (Agenda Item 3). During the discussion of the Commission, some delegations indicated the need
for international control while others noted that at present time there was a lack of knowledge on the real situa-
tion as it existed. Similarly several delegates were of the view that a careful evaluation should be undertaken to
more thoroughly examining the existing evidence as well as evaluating the effect of scheduling substances under
the 1971 Convention on Psychotropic Substances prior to any decision being taken by the Commission.
Reflecting on the criteria that need to be examined and fulfilled before any substance can be scheduled
under the 1971 Convention, one notes that guides are provided in Article 2, Sections 4 and 5 of the said Conven-
tion. These two sections required that:
If the World Health Organisation finds:-
(a) That the substance has the capacity to produce
(i) (1) A state of dependence, and
(2) Central nervous system stimulation or depression resulting in hallucination or disturbances
in motor function or thinking or behaviour or perception or mood, or .
(ii) Similar abuse and similar ill effects as a substance in Schedule I, II, III or IV and
(iii) That there is sufficient evidence that the substance is being or is likely to be abused so as to con-
stitute a public health and social problem warranting the placing of the substance under interna-
tional control, the World Health Organisation shall communicate to the Commission an assess-
ment of the substance, including the extent or likelihood of abuse, the degree of seriousness of the
public health and social problem and the degree of usefulness of the substance in medical therapy,
together with recommendations on control measures, if any, that would be appropriate in the light
of its assessment.
The Commission, taking into account the communication from the World Health Organisation, whose
assessments shall be determinative as to medical and scientific matters and bearing in mind the economic, social,
legal, administrative and other factors it may consider relevant, may add the substance to Schedule I, II, III or
IV. The Commission may seek further information from the World Health Organisation or from other ap-
propriate sources.
In order to assess the impact of scheduling drugs under the 1971 Convention, a study was developed by the
National Drug Research Centre, University of Science Malaysia, which is a United Nations Collaborating Centre
for research and training in Drug Dependence. Based on extensive discussions with scientists from various
regional countries, it was decided that the most effective means of obtaining the necessary information was by
undertaking a questionnaire survey.
The survey instrument was designed by a team of researchers and aimed at eliciting information on:-
(i) The adequacies and/or inadequacies of national controls in the various countries;
(ii) The effect of scheduling drugs under the 1971 Convention on the related drug abuse problem.
Specific information was also gathered on:
(i) the extent of drug abuse including benzodiazepihe abuse;
(ii) the effect of national (legislative) control on the legal and illegal availability of benzodiazepines
within the various countries;
(iii) the impact of international control.
METHODOLOG\
The original research proposal envisaged that the questionnaire instrument would be circulated to all
member countries of the United Nations; however, this approach had to be modified because of technical dif-
ficulties. Thesurvey was altered to study mainly the Anglophone countries in East Asia with one European, two
North American and one African countries. Fifteen countries were finally selected-and every effort was made to
obtain a representative distribution of countries reporting varying levels is of problems associated with abuse of
psychotropic and other psychoactive substances.
As this part of the study - the IMPACT study - only addresses issues relating to the economic, social,
legal and administrative aspects, the information in these areas is discussed has Data obtained on other related
areas such as abuse levels etc. are dealt with in other sections of this report. Further, since the information ob-
tained was voluminous and represented an invaluable resource informiltion for policy planners, the research
team decided to undertake a detailed analysis of the gathered data arid this will be published as a full monograph
in the future. In this section, a summary of the major findings is given.
RESULT
Of the fifteen countries invited to participate in this study, eleven countries completed the necessary ques-
tionnaire instrument ('participating' countries, underlined):
1. Australia
2. Burma
3. Canada
4. Germany
5. Hong Kong
6. India
7. Indonesia
8. Malaysia
9. New Zealand
10. ~geria
11. Pakistan
12. Philippines
13. Singapore
14. Thailand
15. United States of America
Five out of the eleven countries were signatories to the 1971 Convention, the remaining six had not yet ac-
ceded to it. .
(a) Impact of the 1971 Convention
In regards to the actual implementation of the'1971 Convention non-signatory countries envisaged greater
difficulties than signatories. The most commonly reported problem was in relation to administration, where
many countries expressed the view that they had undertaken or will have to carry out extensive changes in their
administrative procedures to implement the Convention effectively.
In many instances it was reported that they would have to redesign their information gathering and drug
monitoring system. Further to ensure uniformity and prevent discrepancies at the national level on drug control,
some scheduling activities would have to be carried out. Several countries, even some who were signatories, in-
dicated that they did not have adequate resources to implement the 1971 Convention properly.
......
Some countries indicated that they would have to make several amendments to their existing legal acts, or-
dinances and regulations to ensure effective implementation.
Participating countries were asked to assess their national control measures with regards to the problems
associatedwith abuse of psychotropic and other psychoactive substances. All except two countries (Pakistan and
Thailand) reported that their existing national controls were adequate to deal with the existing problems caused
by psychotropic and other psychoactive substances. Both in Thailand and Pakistan the problems experienced
were associated with illegal availability, particularly the barbiturate hypnotics, methaqualone and am-
phetamines. Pakistan also indicated that they were currently involved in revising their national laws and with
their enl1ctment these controls should be adequate. Thailand reported that, partly due to the lack of medical per-
Note: "Psychotropic substances" means substances that are listed in the 1971 Convention. "Psychoactive substances" are all CNS -
active substances. .
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sonnel and partly due to the widespread availability of psychotropic and other psychoactive substances which
could easily be obtained through several retail outlets without prescription, additional national control measures
were desirable to deal with the easy availability and abuse problem.
All the participating countries had legislative measures for the control of psychoactive substances. In all
the countries, except for Thailand, psychotropic and other psychoactive substances which were used
therapeutically were available only on prescription. Further national control existed for importation and expor-
tation of these substances. The degree of monitoring/record keeping and inspection procedures varied among
the different countries, though all the participating countries reported having the necessary mechanisms, but not
necessarily the means for implementation.
The participating countries were requested to indicate whether international control would assist them in
resolving their national problems associated with psychoactive substances. Rather surprisingly only three coun-
tries indicated affirmatively. Review of the reasons why the majority of countries felt that international control
would have little or no effect on their national psychoactive drug problems indicated the following:-
J. The existing national controls were considered adequate and in most instances, the level of na-
tional control were more stringent that those called for in the 1971 Convention;
ii. For psychotropic substances in Schedule 1 and 2 of the 1971 Convention, it was opined that na-
tional control still remained the most effective way of dealing with their availability in the respec-
tive countries. International control at the level of Schedule 1 and 2 was stringent, had little if any
impact and it was opined that the 1971 Convention was unable to address the main problem, that
of illegal traffic. Methaqualone and amphetamine were cited as examples.
iii. For psychotropic and other psychoactive substances which are currently used in therapy the pro-
blems of misuse and illegal availability were a consequence of diversion and bad prescribing prac-
tices of a minority of physicians. They were considered to be best dealt with at the national level
through drug enforcement and clinician education.
iv. Several countries, particularly those in the South-East Asian region (Thailand, Malaysia, In-
donesia, Singapore and Hong Kong) considered that their problems associated with psychotropic
substances and other psychoactive drugs were more closely related to the illegal availability and
abuse of counterfeit products which could not be controlled by the 1971 Convention.
Those countries that considered that International Control, had assisted them in dealing with the related
psychotropic substance abuse problem, indicated that: -
i. Placing a substance under International Control, enabled them to regulate the amount of a par-
ticular psychotropic substance being imported into their respective countries. It was pointed out
that the 1971 Convention provides the necessary control procedures for importing and exporting
countries, thereby not hampering trade while maintaining the necessary security among the
signatory countries.
ii. Scheduling a substance under the 1971 Convention, will alert national authorities to the actual or
potential danger of that substance and hence stimulate the authorities to enforce necessary control
measures.
With regards to the 1971 Convention itself, it was the general consensus that the current Convention was
inadequate in many respects and due to the insufficiencies, the 1971 Convention was unable to act as an interna-
tional control instrument.
(b) Potential Impact of Scheduling the Benzodiazepines
Participating countries were asked to describe the national controls that were being applied to control ben-
zodiazepines.
All countries except Thailand reported that benzodiazepines were available only on medical prescription.
In Thailand, with the exception of diazepam injections and nitrazepam, all benzodiazepines could be purchased
easily. In some countries, the purchase, possession and use without medical directive is considered an offence
under their national law. Further, the importation and distribution could be carried out only by authorised
agents. Some countries required the maintainence of sales records for the benzodiazepines.
Countries were asked to assess the effect of current national control measures on the medical use and illicit
use of benzodiazepines. It should be pointed out at this juncture that some of the participating countries, i.e.
Singapore, Malaysia, Philippines, Thailand, had controlled a small number of benzodiazepines under the
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Dangerous Drug Act over and above the normal legislative control for psychoactive substances. The listing of
any psychoactive substance in the Dangerous Drug Act, due to the stringent control measures, invariably
diminished legal availability and obviously, due to enhanced legislative enforcement powers, reduced illegal
availability wherever it existed.
In all countries, the normal legislative measures did not hamper legal availability of benzodiazepines at
hospitals and in medical pra..::tice. Further, since in these countries national controls required the ben-
zodiazepines to be available orly on prescriptions, the legal outlet will be restricted to medical practices and
pharmacies. Pharmacies were a,so required to maintain records of sales, though in some of the countries, these
records represented minimal information.
With regards to illicit availability and use, these countries were unanimous in the view that national laws
were adequa~ to control the diversion of legally imported benzodiazepines and non-medical use. Several of the
countries reported that wherever illegal traffic or misuse of benzodiazepines existed, national control measures
have had significant impact in reducing illegal availability and use.
Thailand on the other hand reported that current national control was inadequate for controlling the pro-
blems associated with benzodiazepines. Since the majority of benzodiazepines were NON PRESCRIPTION
DRUGS, they were readily available from various retail outlets including pharmacies. Further, it was opined
that, since this was a useful therapeutic agent, and that due to a lack of medical personnel especially in the
remote areas, numerous difficulties will be generated by restricting the availability of these substances. It was
fully acknowledged that additional national control was desirable.
Pakistan reported it has adequate national controls to manage the problems associated with the legally im-
ported benzodiazepines. However, in consonance with several other South-East Asian countries, they reported
severe problems stemming from illegally imported benzodiazepines. These illegally imported products, often
brought into the countries by deliberate mislabelling, is sold cheaply to some unethical business outlets. Some of
the countries reported that these illegally imported benzodiazepines have in certain instances proven to not even
contain benzodiazepines but phenobarbitone and/or placebo substrate.
trte national authorities of the participating countries were asked to review the effect of placing the ben-
zodiazepines under international control and the impact of it of the national level. All the participant countries
except Thailand, Philippines and Pakistan, reported that na~inal controls were adequate and that international
control would have no significant impact and hence be unnece sary. Several countries opined that, based on past
experience, international control would have little impact 0 the illicit use (abuse) of benzodiazepines. Further,
several countries reported that the current level of their national control were more stringent than those being
consequential to international control. Some countries argued that international control would be a burden and
may hamper health care practices in their countries. It was opined that placing the benzodiazepines on interna-
tional control would place an additional administrative burden of having to report import/export and use
figures to the International Narcotics Control Board. Also it was stated that international control may be restric-
tive in that their dispensation by health care workers will not be permitted and in several of these countries,
health care workers were the backbone of the health delivery services.
The general consensus of these countries would appear to be that since benzodiazepines were already con-
trolled nationally as prescription drugs, international control would not in anyway significantly enhance control
measures. On the other hand it will impose some financial and certainly additional administrative burden for all
member states. It must be pointed out here, that these countries did not view benzodiazepines as causing a major
drug abuse or public health problem, especially in relation to their own national drug abuse prob~ems. Some
authorities opined that, in their countries where the problem of benzodiazepines abuse was associated with the
use of these substances as secondary drugs of abuse with opiates and also when there were shortages of opiate
supply, too tight a control of the benzodiazepines may cause these abusers to turn to other substitute drugs
which could turn out to be more harmful to the user. All authorities acknowledged that the benzodiazepines if
left totally uncontrolled did have the potential to cause an abuse problem; however, it was emphasised that na-
tional control was the best and most appropriate mechanism for controlling a group of substances which had
wide therapeutic use that did not, in their view, constitute a global problem.
Three countries who called for international control, viewed the need for international control as a means
to reducing availability by restricting the exportation of benzodiazepines by manufacturing countries. Philip-
pines and Pakistan, whilst claiming that national control was adequate to deal with diversion of legally imported
benzodiazepines, felt that international control was necessary to reduce illicit benzodiazepine traffic into their
respective countries and their consequence availability in the illicit market. Thailand, whilst concurring with the
above view, also felt International Control will enhance its law enforcement activities.
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8. SUMMARY, SPECIAL ISSUES AND UNANSWERED QUESTIONS
INTRODUCTION AND BACKGROUND
The 1971 Convention on Psychotropic Substance was designed to facilitate the control of production,
marketing (sales on prescription only), exportation and importation of psychotropic substances which have
dependence producing liability. The Convention specifies the criteria which need to be fulfilled before a
psychoactive substance can be included in the said Convention.
The 1971 Convention states that "the United Nations Commission on Narcotic Drugs, taking into account I
the communication from the World Health Organisation, whose assessment shall be determinative as to medical;
and scientific matters and bearing in mind the economic, social, legal, administrative and other factors it may ,
consider relevant, may add the substance to Schedule I, II, III or IV. The Commission may seek further infor-
mation from the World Health Or~anisationor other appropriate sources".
At its Seventh Special Session the Commission on Narcotic Drugs, adopted a Resolution 2(S~VII) on Pro-
cedures to be followed in matters of scheduling of narcotic drugs and psychotropic substances. As part of that
resolution, the Commission requested Member States for "information on the economic, social, legal and ad-
ministrative factors related to the abuse of substances being considered for possible scheduling, and to supply as
complete data as possible on any illicit trafficking in the substances in question".
METHODOLOGY AND OBJECTIVES
Interested Member States and Scientists, and the Secretariat of the Commission held discussions on possi-
ble avenues for addressing the request of the Commission. The National Drug Research Centre, University of .
Science, Malaysia also was already undertaking an UNFDAC supported study on similar lines, and the Centre
was encouraged to expand the scope and extent of its existing study.
An appropriate survey instrument was designed, sent to concerned scientists for their evaluation and
modified according to comments received. Fifteen anglophone countries were selected for the study and every ef-
fort was made to ensure participation of signatory and non-signatory countries; of countries involved in the pro-
duction and consumption of psychotropic substances as well as countries reporting problems associated with
Psychotropic Substance Abuse. Existing information available from United Nations reports was also analysed
and where appropriate was included in the study.
The main objective of the study was to design a data gathering instrument which would facilitate the com-
prehensive gathering of relevant information which interalia the Commission might carefully consider in fulfill-
ing its functions as envisaged by the 1971 Convention.
The secondary objective was to apply the finalised data gathering instrument to single substance or groups
of substances being considered for possible scheduling by the Commission. As the substance for consideration
by the-CND at its 30th Session in February 1983 was to be the benzodiazepines, this procedure was applied to
these psychoactive substances.
In the development of the study it was suggested that this report should be limited to a review of the
economic, social, legal and administrative factors related to the abuse and illicit traffic as well as to assessment
of the impact of scheduling benzodiazepines under the 1971 Convention. During this study it became clear that,
at present, data on the elements of information required according to 1971 Convention, for consideration by the
Commission existed in several isolated packages. To provide comprehensiveness of information and understan-
ding it was decided that this Report should present an analysis of the current knowledge on all elements of infor-
mation requested in the 1971 Convention.
In accordance with the 1971 Convention this report should be considered as another "appropriate source"
which is complementary and supplementary to reports of the World Health Organisation as well as other na-
tional and international agencies.
SUBSTANCES UNDER REVIEW - The Benzodiazepine Group
Several difficulties were encountered in reviewing these substances, mainly because they have extensive
therapeutic application and as such, the balance between the therapeutic value and the social and public health
risks involved with these drugs needed carefully assessment. The extenSIve therapeutic usefulness of the ben-
zodiazepines is well documented; however, this information on the misuse and abuse of these drugs is in marked
contrast poorly documented. This is probably due to fact that either the effect of abuse is minimal or due to a
general lack of information or both. This inbalance of available information affected the assessment process.
The benzodiazepine drugs belong to the family of the 4,5-benzo(hept)-1 ,2,6-oxidiazines. The individual
31
substances in this group are chemically very similar, but minor differences exist in their potency, therapeutic
usefulness and in the profile of their main actions.
Benzodiazepines as a class are among the most widely used drugs globally. The extensive use of the ben-
zodiazepines has raised the question of overprescription. The evidence in this area is often contradictory. Some
epidemiological studies indicate that there is significant overprescribing of this group of drugs. Other studies
have demonstrated that the benzodiazepines were underprescribed. Irrespective of these contradictions, it has
been suggested that the prescription habits of practising physicians could be improved by appropriate educa-
tional and informational measures.
Consumption figures indicate that the level of consumption in developing countries is much lower than in
industrialised ones. This lower level of consumption may be due to several factors, such as the extent of the
health care facilities that use these drugs and their availability. It is important to note that, in spite of lower levels
of consumption in these countries, overprescription of benzodiazepines has been reported. More data is needed
to clarify the situation.
The abuse of benzodiazepines is a fact, but the ~xtent of this abuse is not clear. True dependence, physical
and psychological, is known to occur with the benzodiazepines, but the frequency of this phenomenon is
debated. There is at present inadequate evidence to enable conclusive differentiation of the dependence potential
between any of the 27 benzodiazepines being considered for possible control. However, in concurrence with the
1982 WHO Panel on the scheduling of psychoactive substance for international control, it is opined that
halazepam has a potential to demonstrate a possible difference; at present the supporting evidence is lacking.
An attempt has also been made to assemble data on the extent of abuse and illicit traffic from different
sources. The existing evidence does not permit a precise conclusion. Nevertheless the following generalisations
may be made.
(a) Several countries are aware and concerned of a benzodiazepine abuse problem, however, few of these
countries (9 in this study) are able to report hard data on the actual number of persons associated with
_, benzodiazepine abuse;
(b) In those countries where hard data was available, (with the exception of Cyprus and Kuwait), the pro-
portion to which benzodiazepines contributed to the overall general drug abuse problem was not signifi-
cant;
(c) In relation to the different benzodiazepine substances, 19 of the 27 substances have been reported to be
associated with abuse problems. Similarly in relation to illicit traffic, several countries have reported
seizures of various benzodiazepine substances;
(d) Combining available elements of information on the abuse and illicit traffic; a general conclusion reach-
ed is that 22 out of the 27 benzodiazepines substances had some association with the problem of abuse
and illicit traffic.
The question that should be considered is "what does all this information mean and to what extent does in-
formation on abuse and illicit traffic reflect the abuse liability of benzodiazepines".
One conclusion that could be drawn from international reports was that the number of reports related to
abuse and amounts of these substances intercepted in illicit traffic had a direct correlation to the availability of
these substances. The Commission has to carefully evaluate this information.
Reviewing responses of countries on the effectiveness of national control and the need for international
control, it appears that more than two-thirds of the countries that participated in the IMPACT study indicated
that national controls were adequate and effective, at the present time, in dealing with benzodiazepine abuse
problems. Several of these countries raised doubts as to the usefulness and value of international control.
However, their main sourceS of concern were not directed at the substances under consideration, but rather at
the 1971 Convention in general. The major concerns expressed were:-
(i) Inefficiency and/or ineffectiveness of the 1971 Convention on Psychotropic Substances;
(ii) Increase in burden of administrative and financial resources to implement and fulfill properly the
requirements of the Convention;
(iii) Perceived restrictions imposed by the Convention on the therapeutic availability of these
substances nationally and particularly to para-medical and health care workers.
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To schedule a particular or all the benzodiazepine substances is the prerogative of the Commission on Nar-
cotic Drugs. Reflecting on the available evidence it is possible to examine the options available to the Commis-
sion.
There is adequate evidence that all the benzodiazepines have a potential to produce dependence. Further,
current evidence does not allow one to differentiate the dependence potential between any of the 27 ben-
zodiazepines.
Existing information indicates that nearly all of the benzodiazepines (22 out of 27) have been associated
with abuse and/or illicit traffic.
Hence, combining both these elements of information, irrespective of whether the Commission decides to
schedule or not schedule these substances, logic dictates that the benzodiazepines should be considered as a
group. The only possible exception is halazepam which, despite the lack of substantive evidence at present, is
opined as having the potential to demonstrate a possible difference. Similarly, irrespective of the decision, it is
essential that the responsible agencies assess and monitor the benzodiazepines abuse situation. This is important
and would indicate any situation change which may necessitate action. A collective effort involving all interested
parties including pharmaceutical industries is advocated.
Should the Commission concur with the above view, then the Commission has to decide, on the basis of
available evidence whether to: -
(i) schedule all the 27 benzodiazepines, and defer consideration of halazepam, as recommended by
the World Health Organisation;
(ii) defer the decision to schedule all 27 benzodiazepines, but continue to monitor on a biannual or an-
nual basis the extent of benzodiazepine abuse;
(iii) not to schedule the benzodiazepines under the 1971 Convention.
Several elements of information should be reviewed by the Commission carefully in reaching its final deci-
sion, inclllding whether the current extent of benzodiazepine abuse constituted a global problem, needing inter-
nanonal control. Several countries have indicated that, at present, national controls are adequate. Others feel
that a situation has been reached necessitating international control. In addressing this issue the Commission
should also take into account that many countries reported that benzodiazepine abuse was closely associated
with illegal products/counterfeits and their illicit traffic. At present the Convention does not address such issues.
Some social scientists may interprete the existing evidence and suggest that at present, in numbers, the ex-
tent of benzodiazepine abuse may not constitute a significant public health and social problem. It must be
reiterated that abuse of benzodiazepines is a faet-. The debate relates directly to the extent of abuse. From a
preventative point of view it may be argued that since there is an acknowledged abuse problem effective interna-
tional control could curb the worsening of the problem.
Another area to be addressed by the Commission is to whether international control would assist parties to
the 1971 Convention. Concerns expressed regarding the 1971 Convention itself should be evaluated. Considera-
tion should also be given to those already overburdened countries which currently have difficulties in fulfilling
the Convention (e.g. prescription control), whether scheduling of these substances will tmly enable these coun-
tries to achieve better control and thus contribute not only to their national but also to global reduction of ben-
zodiazepine abuse.
The Commission must examine all these issues and reach an appropriate conclusion.
CONCLUSION
The objectives 2f the IMPACT study were to develop and apply data gathering methodology to obtain and
assess relevant information on benzodiazepines which the Commission might usefully consider in fulfilling to its
functions as envisaged by the 1971 Convention. The researchers are of the opinion that these objeetives have
been achieved. It is recommended that the developed procedure could be applied to all future psychoactive
substances being considered for scheduling.
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ANNEX
Table 3(i): Consumption of Benzodiazepine Anxiolytics (in 000/1000 inhabitants/day)
adapted from Blaha and Brukmann
1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978
.
Czechoslovakia 0.1 0.3 2.3 3.4 6.2 8.3 10.3 10.2 11.5 12.1 12.6 13.9 13.0
Finland 12.5 16.9 19.8 24.6 18.3 15.5 14.4 14.6 14.9 15.2 14.4
Iceland 49.0 45.0 46.4 47.0 48.0 51.7 55.3
Northern Ireland 9.2 12.5 15.2 19.0 21.0 23.0 25.2 27.3 29.7 32.8 34.2 32.4
Norway 14.8 19.0 25.3 27.4 25.2 24.0 25.4 23.8 23.4 24.2
Sweden 19.2 19.2 17.7 17.7 18.0 18.7 19.0
I I
-
I I
Table 3(ii): Consumption Figures from Various (in kg. unless stated)
't
Country AUSTRALIA CYPRUS HONG KONG
Drug Type 1976/77 1977178 1978/79 1979/80 1980/81 1977 1978 1979 1980 1981 1977 1978 1979 1980 1981
Chlordiazepoxide - - - - - 1,050,380 tab. - 222.6 - - -
Clonazepam - - - - - 37,410 tab. - 0.178 0.261 0.330 NM
10 bottles
Clorazepate - - - - - 330,000 tab. - 0.440 1.670 2.470 -
Diazepam 473 412 382 319 295 4,161,585 tab. - 178.87 8.65 221.37 -
1,833,bottles
Flurazepam - - - - - - - 9.190 9.350 16.820 -
Lorazepam 1,452,000 tab. - 5.770 4.360 8.140 -
Medazepam - - - - - Nil Nil Nil 177,290 tab. NI - 2.436 . 2.133. 2.695 -
Nitrazepam 304.5 313.5 313.5 277 269 547,920 tab. - 3.480 1.460 1.200 -
Oxazepam 1926 2556 3294 3684 4332 45,725 tab. - 4.208 . 7.990 6.230 -
Oxazolam - - - -
- -
- 2.500 4.640 7.860 -
Prazepam -
- - - - -
- 3.876 12.690 3.590 -
Tenazepam - - - -
-
63,000 tab. - 10.160 6.890 3.590 -
Bromazepam - - - - - - NM NM NM NM NM
Flunitrazepam - - -
-
-
- NM NM NM NM NM
INDONESIA JAPAN MALAYSIA
Country
'I
Drug Type 1977 1978 1979 1980 1981 1977 1978 1979 1980 '1981 1977 1978 1979 1980 1981
Chlordiazepoxide 0.347 ~ 24.963 29.122 3.920- 10.528 0.509 - - - - 1.488.
Clonazepam NM NM NM NM NM - - - 0.395 0.603 0.726 0.469
Clorazepate NM NM NM NM NM - - - - 0.75 - -
Diazepam - 0.129 0.128 0.116 - 1750 1959 - 50.512 39.898 4.579 17.617
Flurazepam NM NM NM NM NM - - - 2.012 2.163 2.232 1.425
'.
Lorazepam - 0.003 0.004 - - - - - - - 1.276 -
Medazepam - 0.019 0.015 0.013 - Nil - - Nil Nil - 2.017 1.885 1.739 0.845
Nitrazepam - 0.008 0.013 0.016 - 992 1174 - 3.614 3.383 2.168 1.160
Oxazepam NM NM NM NM NM - - NM NM NM NM NM
Oxazolam NM NM NM NM NM - - NM NM NM NM NM
Prazepam - 0.004 0.003 0.002 - - - - - - - -
Tenazepam - 0.004 0.004 0.004 - - - - - - 2.345 -
Bromazepam - 0.007 0.010 0.013 - - - - 1.509 1.098 0.975 0.529
Flunitrazepam - 0.006 0.833 0.964 - - - - 3.430 4.232 5.501 2.53
Country PHILIPPINES SINGAPORE THAILAND
Drug Type 1977 1978 1979 1980 1981 1977 1978 1979 1980 1981 1977 1978 1979 1980 1981
Chlordiazepoxide 10.298 22.731 31.375 - - - 2.308 1.952 2.290 1.026 - - - 4.020· -
Clonazepam - 0.091 0.566 - - - 0.071 0.071 0.069 0.048 NM NM ·NM NM NM
Clorazepate 0.476 1.310 0.754 - - - - - - - ,NM NM NM NM· NM
Diazepam - 26.373 29.237 32.032 - - 4.383 3.578 3.528 1.943 - - - 6.762 -
Flurazepam 24.018 32.070 29.104 - - - 6.364 7.980 9.002 4.970 - - - 1.328 -
I,
Lorazepam 2.905 2.796 3.012 - - - - - - - - - - 0.162 -
Medazepam 2.177 2.351 0.966 - - - 1.747 1.363 1.198 0.549 - - - 0.943 -
Nitrazepam 4.055 0.925 1.102 - - - 2.504 2.593 2.719 1.410 - - - 1.118 -
Oxazepam 4.995 5.105 5.511 - - - - - - - - - - - -
Oxazolam NM NM NM NM NM NM NM NM NM NM - - - - 0.175
Prazepam NM NM NM NM NM - - - - - - - - 0.385 -
Temazepam NM NM NM NM NM - - - - - - - - 0.125 -
Bromazepam NM NM NM NM NM - 1.129 - 1.228 0.622 NM NM NM NM NM
Flunitrazepam NM NM NM NM NM - 0.596 0.081 0.086 0.038 NM NM NM NM NM
Nm : Not marked
- : Data not available
Table 4(i) Illicit Traffic -1979-1981
f F.R.of~ Argentina Austria Australia Chile Cyprus Denmark Finland Greece Hong Kong Ireland Israel Japan Kuwaitrug ype Germany
Bromazepam + + + + +
Clobazam + + + +
Cloxazolam +
Chlordiazepoxide + + + + + +
Clorezepate + +
Clonazam +
Diazepam + + + + + + + + + +
Flurazepam + + + + +
Flunitrazepam + + + + +
Estazolam +
Lorazepam + +
Nitrazepam + + + +
Nimetazepam +
Medazepam .+ + + + ,
Oxazepam + + + +
Prazepam +
Triazolam +
Temaprazepam
"
Source: Report compiled by the UNITED NATIONS DIVISION OF NARCOTIC DRUGS
~ Malaysia Malta Philippines Portugal Italy Spain Sweden Switzerland Singapore Tunisia Uruguay UnitedDrug Type Norway Kingdom
Bromazepam
Clobazam +
Cloxazolam
..
Chlordiazepoxide + + + + + +
Clorazepate +
Clonazam + + + +
Diazepam + + + + + + + +
Flurazepam + + + + + + + +
Flunitrazepam + + + + + + + + +
Estazolam
Lorazepam + + + +
Nitrazepam + + + + + +
Nimetazepam +
Medazepam + + + +
Oxazepam + + + + + +
Prazepam + + +
Triazolam + +
Temaprazepam +
Ketazolam +
~ U.S.A. Guatemala New Zealand Sri L~nka South AfricaDrugTy~e
Brozemapam
Clobazam
Cloxazolom
Chlordiazepoxide + + +
Clorazepate + +
Clonazam +
Diazepam + + + + +
-
Flurazepam + +
Flunitrazepam
Estazolam
Lorazepam + + +
Nitrazepam + + + +
Nimetazepam
Medazepam +
Oxazepam + + +
Prazepam + +
Triazolam
Temaprazepam
Ketazolam
Table 4(ii): Illicit Trafic • Amount of Seizures for 1979, 1980 and 1981
Country CYPRUS DENMARK HONG KONG AUSTRIA SINGAPORE
Drug Type 1979 1980 1981 1979 1980 1981 1979 1980 1981 1979 1980 1981 1979 1980 1981
Diazepam 813mg. 841 tab. 347 tab. 1186 tab. 83622 tab.· 165 tab. 4 amp.
9.5g. 7 amp.
powder
Flurazepam - 503 tab. 57 tab.
Nitrazepam - 16 tab. 13 tab. 1336 tab. 392 tab.
Chlordiazepoxide 131mg. 8903 tab. 4472 tab.
Medazepam Traces. 300 tab. -
Oxazepam Traces. 646 tab. 60 tab.
Clorazepam 160m~.
Lorazepam - 276 tab. -
Clonazepam - 30 tab. 21 tab.
Prazepam - 300 tab. -
Tempazepam - - .9 tab.
Flunitrazepam - - 5 tab. 130 tab 15006 tab. 36001 tab.
Nitetazepam - 2 tab.
Triazolam
- - 3 tab. 13 tab. 15 tab. 60 tab.
BromazepaIll - - 22 tab. 99 tab.
Clobazam - - 28 tab. 161 tab
Source 1: Report compiled by the UNITED NATIONS DIVISION OF NARCOTIC DRUGS
Source 2: IMPACT STUDY
Country PHILIPPINES AUSTRALIA Gf:RMANY PORTUGAL MALAYSIA
,
,
",--
Drug Type 1979 1980 1981 1979 1980 1981 1979 1980 1981 1979 1980 1981 1979 1980 1981
Diazepam 239,~ 2,326 14 amp. 31 Imp. 20mg. 648 tab. 9445 tab. 13620 tab.
D_ . D.U. 592 tab. 165 tab. 9 amp.
5.1 g. 567 tab.
--
Flurazepan 338 D.U. 46 D.U. 36 cap. / - - - 150 cap. 257 cap. 10 tab. 37tab.
"
Nitrazepam 65,432 67,066 179 tab. 40 tab. - - - - 585 tab. 313 tab.
D.U. D.U.
Chlordiazepoxide 18 cap. - - 15 cap. 650 cap. - 17,712 12,388
191 tab. 5 tab. tab tab.
Medazepam 55 tab. 25 cap. )- - - 189 cap. 160 tab. -
-.
Oxazepam 362 tab. 148 tab. - 100 tab. 45 tab. 10 tab. 56 tab. -
Clorazepate 10 cap. 31 cap. - -
663 tab.
5 amp.
Lorazepam 96 tab. 398 tab. 948 tab. 86 tab.
Clonazepam 2 tab. 2 tab.
Prazepam 133 tab. -
Flunitrazepam 25 tab. 340 tab. 1767 - -
,8 mg. tab.
Bromazepam 1 tab.
Clobazam 50 tab.
Illicit Traffic - Amount of Seizures for 1979, 1980 and 1981
Illicit Traffic - Amount of Seizures in D.U. unless stated
Country/ NEW ZEALAND PHILIPPINES SRI LANKA
Years
Drug Type 1978 1979 1980 1978 1979 1980 1979 1980 1981
Chlordiazepoxide 33 31 46 500 - - - - -
Clorazepate
- 1 - 207
-
- - -
-
Diazepam 1109 714 2621 122,637 239,256 2,326 210 tabs. 190 tabs. 66 tabs.
Lorazepam 39 112 60 - - - - - -
Flurazepam
-
- - 20 .338 46 - - -
Nitrazepam 579 245 261 64,500 65,432 67,066 - - -
Oxazepam 81 71 143 - - - -
- -
Country FINLAND JAPAN NORWAY
Drug Type
..
1979 1980 1981 1979 1980 1981 1979 1980 1981
Diazepam
Flurazepam
Nitrazepam
Chlordiazepoxide
Medazepam
Oxazepam
Clorazepam
Lorazepam
Cloxazolam 292 g.
Estazolam 12 g,
Flunitrazepam 115 tab. 15 tab. 143 tah.
Bromazepam 15 g.
Ninetazepam 7 g.
o'
Country IRELAND MALTA
Drug Type 1979 1980 1981 1979 1980 1981
Diazepam 954 tab. 200 tab. -
Flurazeapam 1,129 - 2 tab.
tab.
Nitrazepam 2 tab.
Chlordiazepoxide
Medazepam
Oxazepam
Clorazepam
Lorazepam 1 tab.
Clonazepam
Prazepam 1 tab.
Flunitrazepam Bromazepam
Bromazepam
Clobazam
Illicit Drug Traffic in the United States of America
.Drug Type July '75 - April '82 Oct. '77- Jan. '74 - Apr. '82 July '75 - Dec. '76 -Apr. '82 Apr. '82 Apr. '82
Seizures Chlordia- Clonazepam Clorazepate Diazepam Flurazepam Lolltzepam Medazepam Nitnizepam Oxazepam Prazepam
zepoxide
..
Amourit seized in 153,000 160 6.7 21,600 10,000 9,313 104,114 2,009 18,898 1---·640
dosage units million tablets
(unless stated)
Number of 217 2 36 1,519 109 14 3 20 39 8
cases involved
Table 4(iii)
Are Benzodiazepines Does a Benzodiazepine Has Illicit Traffic
Country Available in Your Abuse Problem Endangering been Reported
Market Public Health Exist
Australia + + +
Austria + - +
Belgium + + Nil
Brazil + - Nil
Burma + + -
Canada + - +
Central African Republic + Nil Nil
Cuba + - Nil
Cyprus + + Nil
Czechoslovakia + Nil
-
Denmark + + Nil
Egypt + - Nil
France + + Nil
German Democratic
Republic + - Nil
German Federal Republic + Nil +
Greece Nil - +
Guatemala Nil Nil +
Haiti
-
-
-
Honduras + - Nil
Hong Kong + + +
Hungary + - Nil
Iceland + Nil Nil
Iraq + Nil
-
Ireland + Nil Nil
India + -
-
Indonesia + + Nil
Japan + - Nil
Kuwait + Nil
-
Liechtenstein Nil Nil
-
Source: Report compiled by the UNITED NATIONS DIVISION OF NARCOTICS DRUGS 1981/1982
Are Benzodiazepines Does a Benzodiazepine Has Illicit Traffic
Country Available in Your
Abuse Problem Endangering been Reported
Market Public Health Exist
Madagascar + +
-
Malaysia +
- +
New Zealand +
-
-
Norway +
Nil Nil
Pakistan +
- Nil
Papua New Guinea +
-
-
Philippines + +
+
Poland +
-
-
Qatar + Nil
-
Senegal +
- Nil
Seychelles +
-
-
Singapore +
Nil -
South Africa +
Nil -
.
+Spain +
+
Sri Lanka +
Nil +
~eden + + +
Switzerland +
- Nil
Thailand + +
-
Tonga +
- -
Trinidad and Tobago +
- -
Turkey + +
Nil
Tunisia +
-
-
Tuvalu
-
- -
United Arab Emirates + Nil Nil
United Kingdom + Nil +
United States of America + + +
Yugoslavia + Nil
Nil
Z:jlmbia + - -
Nil - No Information available
Table 4(iv): ABUSE - DATA
German~ Australia Austria Belgium Burma CYPJJlS Chile Denmark France Democratic Honduras Hong Kong Iran Kuwait MadagascarDrug Type Republic
Alprazolam +
Bromazepam + + + + +
Camazepam +
Clobazam + + + +
Chlordiazepoxide +
Diazepam + + +
Estazolam +
Flunitrazepam + + + + +
Flurazepam +
Kelazolam +
Lorazepam +
Clorazepate
Nitrazepam + +
Nordazepam +
Oxazepam +
Triazolam + +
Cloxazolam +
Clonazepam
Prazepam
Source: Report compiled by the UNITED NATIONS DIVISION OF NARCOTIC DRUGS 1981/1982
II.
~ntrY Philippines Singapore Sweden Switzerland Turkey Malaysia U.S.A.
. Drug Type "--'
Alprazolam +
Bromazepam +
Camazepam
Clobazam + '.
Chlordiazepoxide + +
Diazepam + +
Estazolam
Flunitrazepam + +
Flurazepam + + +
Kelazolam +
Lorazepam + + +
Clorazepate
Nitrazepam + +
Nordazepam
Oxazepam + +
Triazolam
Cloxazolam
Clonazepam T-
e'_
Prazepam +
Table 4(v): ABUSE -DATA
No. of cases
SINGAPORE PHILIPPINES KUWAIT SWITZERLAND HONG KONGof abus·~ CHILE
Drug Type 1979 1980 1981 1979 1980 1981 1979 1980 1981 1979 1980 1981 1979 1980 1981 1979 1980 1981
Diazepam 375 I 14 15 2 40 40
Nitrazepam 140 1
Oxazepam 3 1
Flunitrazepam 175
Lorazepam 71
Clonazepam 35 1 1
Flurazepam 145 4 1
Chlordiazepoxide 1 1 7 1 I 20 21
Clorazepate I I I 1 t II I I i
ABUSE - DATA
No. of cases Cyprus Australia
Drug Type 1980 1978 - 1979
Chlordiazepoxide 5
-
Clorazepate 1
-
Diazepam 13 112
Medazepam 1
-
-'
Oxazepam 1 138
Nitrazepam
-
50
Table 4(vi): Table Showing General Drug Abuse, Opiate Abuse and Benzodiazepine Abuse in 1980 ! 1'1 S I
Population Number of Persons Number of Persons Number of Cases of ~",\ l) 't C (.~ ..L<:')Country (in millions) Arrested for General Arrested for Opiate Benzodiazepines AbuseDrug Abuse Abuse
1"15:-;) I'HI 1:0 / , :1 C1 (~) I • >;0 - c ,: ,.',; U
Algeria 18.59 461 (;' """ NilN
Argentina 27.06 2,023 -d i 7Qo 60 - Ii/It Nil
Australia 14.62 23,764 - 1'1/ L/-'6I-f- 2032 -:J 110 300'
Austria 7.56 4,900 dlo) 1422
I~~\. \.-,C\ y-v, c:v j
Bangladesh 87.66 290- ;)()b 33 ~(O
Barbados 0.25 226- ,J
Belgium 9.86 1,630 ,- 45 -
Brazil 123.03 2,498 - Nil
Bulgaria 8.86 Nil -, Nil 41
'. , ..~
,~
2)48 <10 'S :;.J i ;J0),Burma 35.3 2345
Burundi 4.51 Nil r< ~ Nil
Cameroon 84 - lOCo
Canada 23.94 38,498 50, ddJf 436 1010
Jc
Chile 11.10 1,889 - 1,11-0 r~ 2
It-
Population Number of Person~ Number of Persons Number of Cases of
Country (in millions)' Arrested for General Arrested for Opiate Benzodiazepines AbuseDrug Abuse Abuse
/7 r;(1) /38 I 1q(; r
Colombia 27.09 1,492 f59d Nil
Costa Rica 2.24 10 l' Nil
Cyprus 0.63 43 40 2 21
Czechoslovakia 15.32 6 - 55
Denmark 5.12 3,126 3/J.f, Nil
Djibouti Nil 3 c-_O Nil
Egypt 41.99 8,658 7/°7 Nil
Finland 4.78 Nil --3(',1+ Nil
France 53.71 10,958 ! 3650 3610 ') Nil
French
Polynesia 0.16 126 /':;5
iGerman
Democratic j~Republic 16.74 63 25 - 11
,., I [ ~:.t
German Federal (J1)~Cb .,,~.::' 'Republic 61.56 55,447 Nil 18 ! vV
Greece 9.6 536 ]32 54 ~, '': II
",,"_." <:;.<. I
Grenada 0.10 112

..
"-
Population . Number of Persons Number of Persons Number of Cases ofCountry (in millions) Arrested for General Arrested for Opiate Benzodiazepines AbuseDrug Abuse Abuse
Kenya / 16.4 6,448 Nil Nil
Korea 17.91 655 ~p:; 35 -31 Nil
Kuwait 1.37 189 ~)3 37 _. =; 23
Lebanon 3.16 263 ~S;( 115
Lesotho 1.34 339 - 4b2 Nil
Liechtenstein 0.03 28 5 --" ( /
Luxembourg 0.36 66 ?oS] 47
Madagascar 8.74 614 SC:o I
Malaysia 13.44 5,660 5b£0 4962 7 ilL! 4. .N/I-- I I " I
Malta 0.36 73
Mauritius 0.96 356 4d.b 91 (3::/
Mexico 71.91 2,883 L(:] 63 443 3'27
Monaco 0.03 35 35 9
Morocco 20.24 3,996 77 ~I Nil
Netherlands 14.14 7,153 8q 2917 - 3 1bLfI
Popdation Number of Persons
Number of Persons
Number of Cases ofCountry Arrested for General Arrested for Opiate(in millions) Drug Abuse Abuse Benzodiazepines Abuse
Netherlands 0.27 481 - 80lf Nil -)
Antilles
-~
0.15 19
New Caledonia
3.10 6,257 (J 7 NilDOr
New Zealand
77.08 1,259 -(35:) Nil
Nigeria
4.09 4,048 ':7 Nil
Norway
82.44 13,991 - ! Ilq;) 2048 - 43S/
Pakistan
1.84 I,;) ~ r
Panama
48.40 3, 100 Nil
Philippines
35.58 169 U ~I Nil -- is
Poland
Ii .J
22.27
Romania
81. Vincent and 0.12 99 Cfr,0
the Grenadines
Singapore 2.39 3,288 I' ;)6 2849 - H-°19-II
South Africa 29.29 32,170 ')~, ) .:»
Sri Lanka 14.74 Nil Nil
(, _ 0 loq,)o
->\:Jw/V\
I
I
Population Number of PersolfJ Number of Persons Number of Cases ofCountry Arrested for General Arrested for Opiate(in millions) Drug Abuse Abuse Benzodiazepines Abuse
Sweden 5,219 -, /1 '98.31 0--'- i Nil
Switzerland 6.37 8,224 9699 Nil
Thailand 47.17 Sf (02 - (Ilf I) X
/Togo 2.7 84 I;;, 50c , 81
Tunisia 6.37 156 - T9
Turkey 44.92 3,418 " 297 - 5G0
Turks and
~,
Caicos Island 63 .--" Nil
) _J
United
Kingdom 05.95 18,366 ~- ':; 1519
- 1.4-1b
United States
! of America 227.66 12,158 2080
- 2!5:J- I
Union of Soviet
Socialist
:)SRepublic 265.54 27 2 - ;:J..
Venezuela 993 t'/ r13.91 ~-o 2
Yemen 5.93 Nil Nil
Yugoslavia 178 130,'22.34 J 87
- S?cr
Zambia 23.94 9
Opiates: Heroin, Morphine, and other opiates.
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